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Abstract
Spinal cord injury (SCI) remains one of the most devastating conditions in medicine; it is a
complex medical condition with no cure currently available. Inflammation plays an important
role in SCI as it can have both beneficial and detrimental effects. Cell therapy has emerged as
a promising treatment for SCI due to the potential for stem cells, including multipotent
mesenchymal stromal cells (MSC), for tissue regeneration and immunomodulation of the
inflammatory cascade after the initial trauma. However, there are still important, unresolved
questions regarding cell therapy that magnetic resonance imaging (MRI) can help to address
by producing high-resolution images with exquisite soft tissue contrast in a non-invasive,
non-destructive and three-dimensional (3D) manner, allowing a dynamic view of changing
pathology and cellular events in vivo.
In this thesis in vivo longitudinal imaging of SCI in mouse and rat models is presented using
MRI. A resolution of 200µm in all three planes was achieved using a balanced steady state
free precession (bSSFP) pulse sequence in a 3T whole-body clinical scanner. Using iron
oxide particles as a contrast agent, cellular MRI was used to assess direct MSC
transplantation in a mouse model and acute inflammation in a rat model. This was the first
study to use cellular MRI for cell tracking in a mouse SCI model. We report on the use of
cellular MRI to locate transplanted cells and monitor their overall distribution as well as to
evaluate the delivery of transplanted cells to the target tissue in the early phase. Limitations
of long-term cell tracking using iron oxide are also discussed. This is also the first study
using cellular MRI to image in vivo cells associated with the inflammatory response within
the lesion in a rat SCI model and the first demonstration of the use of bSSFP at 3T for rat
body imaging.
Having the tools for longitudinal in vivo cell monitoring in SCI will help gain a better
understanding of both inflammation and response to cell therapy. As these tools are refined,
they can be used to test different potential treatments for SCI and optimize them.
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Chapter 1

1

General Introduction

Spinal cord injury (SCI) is one of the most devastating conditions in medicine; besides
the lives lost, for those who survive, there is a loss of productive life years and a high
economic burden placed on our society. It is difficult to determine the world wide
incidence and prevalence of SCI1, 2 but it is estimated that there are 4,259 new cases in
Canada each year; 42% of these cases are traumatic injuries and 58% result from nontraumatic causes.3 In Canada the primary cause for SCI is car collisions, which account
for 35% of cases. Falls are the second largest cause, producing 16.5% of the new
injuries.4 This chapter will include a general overview of the spinal cord, injury
mechanisms, magnetic resonance imaging (MRI), and cellular MRI.

1.1 The Spinal Cord
The central nervous system (CNS) includes the brain and the spinal cord. The spinal cord
has been described as the “highway” connecting the brain to the rest of the body. This
highway carries information through the ascending (sensory) tracts to the brain and
through descending (motor) tracts to the rest of the body. The human spinal cord can be
divided in segments according to the spinal nerve pairs that enter and leave the spinal
cord: 8 cervical, 12 thoracic, 5 lumbar 5 sacral, and 1 coccygeal.5 The spinal cord is
surrounded and protected by connective tissue, called the spinal meninges: the pia mater,
adhered to the surface of the spinal cord; the arachnoid mater, which encloses the
subarachnoid space, where the cerebrospinal fluid (CSF) is contained; and the dura mater,
attached to the spinal canal within the vertebral column. Besides neurons, other
supporting cells are present in the spinal cord: oligodendrocytes, which form a myelin
sheath around axons; astrocytes, which surround blood vessels, helping to form the blood
brain barrier (BBB) and holding structures together; microglia, which are the resident
macrophages of the CNS; and, ependymal cells, another element of the BBB, lining the
spinal canal.6
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Figure 1.1: The spinal cord connects the brain to the rest of the body, serving as a
highway of information that transmits and integrates incoming and outgoing information.
Modified from the NIH Office of Science Education.7

1.2 Spinal Cord Injury
When the spinal cord is injured, the communication pathways between the brain and the
rest of the body are interrupted. Besides the more evident consequence of decreased
muscle control and paralysis, other effects from SCI may include: loss of sensation,
diminished thermal and blood pressure regulation, decreased breathing capacity, loss of
bladder and bowel control, spasticity, autonomic dysreflexia, sexual dysfunction, and
pain.8

1.2.1

Primary Traumatic Spinal Cord Injury

The primary traumatic injury is usually the result of an initial impact to the cord due to a
fracture, dislocation, foreign object impact, or a ruptured disc, combined with a persisting
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compression. In some cases this results in a laceration or even complete transection.9 The
mechanical injury causes immediate cell death at the site of impact and disrupts the blood
spinal cord barrier.

Figure 1.2: The initial injury to the spinal cord produces blood spinal cord barrier
disruption and cell death at the point of injury. This figure illustrates a cervical SCI,
where a bone fragment has impacted the cord.

1.2.2

Secondary Injury

Impaired sensory and motor function in people who have a SCI comes not only from the
initial traumatic event, but also from a ‘secondary’ injury, which further damages the
neural pathways, exacerbating motor and sensory deficits. These secondary processes
include hypoxia, excitotoxicity, and lipid peroxidation, and will trigger an inflammatory
response causing additional cell death.10 The consequences of this ‘secondary’ injury
commonly include: hemorrhage, edema, necrosis, demyelination and cyst formation.11

1.2.3

Inflammation In SCI

The inflammatory response after SCI is triggered by cells within the damaged tissue (e.g.
endothelial cells) that will release pro-inflammatory cytokines and chemoattractants.12
This results in an influx of leukocytes, with different timelines for specific cells. In
humans, neutrophils will enter the cord within 4 hours after SCI, with maximum
distribution in the gray matter (GM) and white matter (WM) at 1-3 days, and will cease
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to enter by 10 days. Peripheral macrophages will be most abundant in the cord at 5-10
days after SCI, and then their influx slowly decreases with time, although they may still
be present for weeks to months. Microglia become activated 1-3 days after injury,
becoming ‘foamy’ macrophages by 5-10 days, and persisting for weeks and up to a
year.13
Inflammation due to SCI in rats has a similar timeline. This has been described by Sroga
et. al who showed that neutrophils appear at the lesion site within a few hours of the
initial injury, reach a peak 12-24 hours after the injury and then disappear by 5 days.
They also showed that, like in human SCI, macrophages infiltrate the cord 2 days after
the injury, reaching a peak 5-7 days after SCI and microglia become activated within
minutes to hours after the SCI, both persisting for weeks to months.14
In mouse SCI there is a similar time course for infiltration and activation of macrophages
and microglia; however, the neutrophil response is different. The initial neutrophil
infiltration still starts within hours after SCI, and the peak is reached 3-7 days after
injury, depending on strain. However, in mice neutrophils increase again 2 weeks after
injury and are still present at the SCI up to 6 weeks after injury.15
Macrophages were considered to have a dual, ‘double-edged’ role in SCI.16,

17

Recent

literature has shown that this may be in fact due to two separate subsets of macrophages
present at the lesion site.18, 19 Classically activated macrophages (M1) are thought to have
a negative role in SCI by exacerbating the injury through the release of toxic by-products
and by amplifying the inflammatory responses. Alternatively activated macrophages
(M2), have been shown to have a positive role in SCI by contributing to the debridement
and healing process.18 Furthermore, Kigerl et al. have shown that during the first 1-3 days
after SCI the presence of M1 and M2 is equivalent, but by the end of the first week the
M2 have mostly disappeared and the M1 dominate.18

1.2.4

Animal Models

In order to better understand the mechanisms of SCI and to explore potential treatments,
animal models of SCI have been developed. Different methods have been used to mimic
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the initial mechanical injury that occurs during SCI in humans, such as contusion,20
compression,21, 22 and transection.23 In this thesis a clip compression model is used which
involves the use of a modified aneurysm clip. The clip uses a C-shaped spring that can be
calibrated to close at a chosen force such as: 3g, 8g, 24g for mouse or 20g, 35g, 50g for
rat, that will result in different severities of SCI (mild, moderate, severe, respectively).22,
24

A laminectomy is performed to expose the cord at the level where the injury will be

induced; 4th thoracic (T4) in this thesis. The clip is placed around the cord extradurally
with one blade of the clip placed on the ventral side of the cord and the other blade on the
dorsal portion; the calibrated spring is then released and left closed for 1 minute. Then the
clip is removed, muscle and skin layers closed, and the animal is allowed to recover from
surgery. The clip compression mimics mechanisms that occur in human SCI as it has two
components, an initial quick contusion and a sustained compression that results in
ischemia. The clip compression SCI model can be performed with low variability. Joshi
and Fehlings22 and Fehlings and Tator25 showed a strong correlation between the scoring
for behavioral testing, histological outcomes, and the severity of SCI in mouse and rat
models, respectively.
Rodents are most commonly used as the animal model for SCI. Rats have been used
most widely26 due in part to size and model development (the first model described was
in dogs and initially adapted to rats), preference and availability27 and, most importantly,
pathology similarities to SCI in humans.13, 14 Differences in the inflammatory responses
to SCI for rats and mice are described in the previous subsection (1.2.3).

These

differences contribute to differences in the appearance of the lesion. The lesion in rats is
characterized by extensive degeneration of GM and WM, apparent at 1 week post-injury,
which increases as rats develop cysts filled with substantial debris.28 In mice the relative
lesion (with respect to cord size) is initially larger but mice show wound contraction as
connective tissue develops at the lesion site similar to the process observed in skin
wounds; another feature in the mice is that they do present small cavities initially, but
these disappear over time.28
Mice have become an increasingly popular model due to the availability of transgenic
strains. Transgenic mice are genetically modified such that either a gene is removed to
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study function loss related to that gene or an exogenous gene is added to study function
gain and better understand the role of each gene in different functions.29 Use of
transgenic mice in SCI research has allowed for a better understanding of the
pathological consequences of SCI; for example, to study the role proteins such as EphA4
(ephrin type-A receptor 4) and GFAP (glial fibrillary acidic protein) will play in the
formation of glial scar or the role of LIF (leukemia inhibitory factor) protein in enhancing
the microglial/macrophage response.30,

31

Transgenic mice can also be used to study

factors that affect axonal regeneration such as Nogo (Neurite outgrowth inhibitory
molecule), MAG (myelin associated glycoprotein), OMgp (oligodendrocyte myelin
glycoprotein) or interactions among them. 29
Rodent models are also widely used to study regenerative treatments for SCI.32,

33

Luchetti et al. compared SCI in immune-competent C57BL/6 and BUB/BnJ mice and
non-obese diabetic severe combined immunodeficient (NOD-SCID) mice to investigate
potential differences in the inflammatory responses that might impact stem cell
transplantation for SCI. The authors reported that there were no differences in the
inflammatory response that would affect neurotransplantation studies; while there were
some variations in neutrophil infiltration, macrophage/microglia numbers present at the
lesion were not different among strains and there was no significant difference in lesion
volume between strains either.34

1.3 Stem Cells
Stem cells are fundamental in the formation of all multi-cellular organisms.35 They have
the unique characteristics of unlimited self-renewal and the ability to differentiate.
Totipotent stem cells can differentiate into any type of cell, pluripotent cells can
differentiate into any type of cell in the body except those needed to support and develop
a fetus in the womb (amnion, chorion, and other components of the placenta), multipotent
cells can differentiate into a variety of cell types (though usually only into cell types from
the same tissue where they are located) and unipotent cells have dedicated differentiation
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to one linage.35 When a stem cell divides, each new cell has the potential either to remain
a stem cell or become another type of cell with a more specialized function.
The term “stem cell” has been around for over a century now36 but it was in the late 50’s
and 60’s when research and many clinical trials started using adult stem cells for cancer
treatment,37, 38 which is thought of as the first therapeutic use of stem cells. It has only
been in the last 30 years that the term “embryonic stem cell” was coined39 and that
research in the stem cell field has really boomed. Some of the most important questions
currently being pursued in stem cell research are: “What are the core genetic and
epigenetic regulators of stem cells? What are the extrinsic, environmental factors that
influence stem cell renewal and differentiation? And how can the answers to the first two
questions be harnessed for clinical benefit?”40 While a lot of effort has been geared
towards defining what is a “true stem cell”41 one thing agreed on is the classification
according to their origin, into embryonic and adult stem cells.

1.3.1

Embryonic Stem Cells (ESC)

First named in 1981 by Martin,39 these cells are derived from the inner cell mass of the
blastocyst and are pluripotent, they can produce cells of all 3 germ layers (mesoderm,
endoderm and ectoderm) that can differentiate in all types of adult tissues.

Figure 1.3: Embryonic Stem Cells are derived from the inner cell mass in blastocyst
and are pluripotent, they have the potential to differentiate into all cells present in adult
tissues.
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ESC gained a lot of attention as a promising therapy for incurable diseases due to their
potential to differentiate into any type of adult tissue and the fact that they can be grown
in vitro almost indefinitely without loosing their self-renewal or differentiation
potential.42 However, ESC also pose potential risks. Most worrisome is the possibility for
teratoma formation due precisely to their capability to maintain their differentiation
potential for long periods of time and be able to differentiate into cells from all 3 germ
layers, so they are unlikely to be used for therapy in their undifferentiated state.42 This
has been reported in both experimental and clinical ESC transplantation research.43, 44
In SCI, embryonic stem cells have been studied in models for several years45-47 but due to
regulatory caution clinical studies are just beginning, in the US through Geron
Corporation.48, 49

1.3.2

Adult Stem Cells

Adult stem cells can be derived from various tissues, including bone marrow (BM),
peripheral blood, brain, spinal cord, dental pulp, blood vessels, skeletal muscle, epithelia
of the skin and digestive system, cornea, retina, liver, and pancreas.35 Adult stem cells are
found in the postnatal organism, where they function as the internal repair system. Their
capacity for self-renewal varies by tissue. For example, in the gut and BM stem cells
regularly divide to repair and replace worn out or damaged tissues, while in the pancreas
and heart, stem cells only divide under special conditions. Adult stem cells are capable of
differentiation, though usually only into cell types from the same tissue where they are
located, thus being labeled multipotent or unipotent.40 On the other hand, they have also
shown plasticity50 and pluripotency51.
Within the adult stem cells, BM-derived stem cells have gotten a lot of attention for their
potential for autologus transplant, where the cells are obtained from the patients own BM
and expanded in vitro, and so avoid rejection. Another feature that makes them an
attractive option for transplantation is that, unlike ESC, they are not associated with
tumor formation and do not present the same ethic concerns ESC do. BM-derived stem
cells can be divided into Hematopoietic Stem Cells (HSC) and Multipotent Mesenchymal
Stromal Cells (MSC).
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1.3.2.1

Hematopoietic Stem Cells (HSC)

HSC can be found in the blood and BM and will form blood components: erythrocytes,
platelets, and immune cells (lymphocytes, monocytes, neutrophils, eosinophils and
basophils).35

Figure 1.4: Hematopoietic Stem Cells can differentiate in blood and immune cells and
can be found in the BM and blood. From W ikipedia’s “Blood cells differentiation chart”
A uthor: パタゴニア Used under the Creative Commons A ttribution-Share A like 3.0
Unported license.
HSC are the stem cells that have been used in therapy the longest, and are still currently
routinely used for treatment of leukemia52,

53

and other disorders such as immune

deficiencies.54 In the context of SCI, they have been used in animal models,55, 56 where
functional recovery was reported as assessed by locomotor testing. They have also been
used for SCI patients in clinical trials which used direct transplantation of HSC into the
cord,57 where improvement in both motor function and sensation was reported, and HSC
delivered by lumbar puncture was feasible, safe, and well tolerated by the patients
involved in the study.58
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1.3.2.2

Multipotent Mesenchymal Stromal Cells (MSC):

As mentioned in this section’s introduction, a lot of effort has been geared towards
defining a “true stem cell” and MSC have been no exception. This acronym has been
used for both mesenchymal stem cells and for multipotent mesenchymal stromal cells.
This nomenclature is accepted as long as it is clearly defined in each publication.59 In the
work presented here, MSC stands for multipotent mesenchymal stromal cells, which are
defined as plastic-adherent cells derived from BM, adipose and other tissues that have
shown multipotency in vitro; while the phrase mesenchymal stem cells is to be reserved
for plastic-adherent cells that can self-renew long term and show multipotency in vivo.59

Figure 1.5: BM-derived multipotent mesenchymal stromal cells can differentiate into
cells from different types of tissues. ©2001 Terese W inslow (assisted by Lydia Kibiuk
and Caitlin Duckwall). Used here with kind permission from T. W inslow.
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MSC can be derived from many different tissues, including BM, adipose tissue, and
muscle, and have the potential to differentiate into bone, fat, cartilage and muscle.60
There is substantial ongoing research in the field, but specifically applicable to SCI is the
fact that MSC have also shown to differentiate into neural cells.61, 62
In the last decade MSC have been explored as an option to promote functional recovery
following SCI. For example, in a rat model Cızkova et al. reported remyelination of
spared white matter tracts and enhanced axonal growth that was reflected in motor
improvement, which was assessed using the Basso–Beattie–Bresnahan behavioral test.63
Lee et al. also reported some motor and sensory recovery using the Basso–Beattie–
Bresnahan scale, improved conductivity in the sensory components of the cord measured
through somatosensory evoked potentials (SSEP), and neural differentiation.64 In a nonhuman primate model, neurogenesis has been reported as well as functional improvement
as measured by SSEP.65
In the last 5 years a few clinical studies using autologous MSC transplant for spinal cord
injury have been done. In one of the first studies Sykova et al. (Czech Republic) used unmanipulated BM, which contained both MSC and HSC, for transplant into 20 patients
divided in 2 groups: chronic and subacute SCI, either by intravenous (i.v.) or intra-arterial
(i.a.) infusion. In this study improved motor and sensory function after three months was
observed mostly in subacute patients that had received the i.a. infusion.66 In another study
by Moviglia et al. (Argentina) MSC were co-cultured with the patients’ own T-cells and
injected in 2 chronic SCI patients by i.a. infusion. Both patients showed motor and
sensory improvement.67 Other reports have followed; Chernykh et al. (Russia) also used
whole BM, containing both MSC and HSC, and performed both direct and i.v. delivery of
the cells in patients with chronic SCI and reported the procedure was feasible, safe and
improved neurological status in the patients that received the treatment versus controls.68
A study in India where BM-derived MSC were transplanted by lumbar puncture in 30
SCI patients reported safety and some sensory recovery.69 Contrary to the previous
positive reports, a more recent study by Kishk et al. (Egypt) where an intrathecal
transplant of MSC was performed in 44 SCI patients reported no significant neurological
improvement but suggests caution as negative effects included spasticity and neuropathic
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pain and one patient with a history of post-infectious myelitis presented post-transplant
encephalomyelitis.70 A new study from Korea explored the use of adipose tissue-derived
MSC and reported no adverse effects after autologous i.v. transplantation in 8 chronic
SCI patients.71 With most of these initial findings reporting safety and feasibility, more
studies are likely to come, particularly since one has raised concerns for adverse effects.
These studies have been in small groups of patients so larger trials are needed. One of the
issues is that makes it difficult to establish the pure effects from MSC transplantation in
these studies is that the transplant protocols have used a combination of cell population,
or concurrent pharmaceutical and/or rehabilitation regimes.

1.3.3

Cell Therapies

It is now being understood that cell therapies are likely to exert their effects by two
mechansisms; replacement of the tissue and trophic support.72 Phenotypic replacement
involves the integration of transplanted cells to damaged tissue according to specific
diseases.

For example, transplanted cells could differentiate into neurons for SCI,

Parkinson’s disease, or traumatic brain injury; into oligodendrocytes for remyelination; or
into motor neurons or astrocytes that would provide neuroprotection. On the other hand
transplanted cells could provide trophic support by releasing growth factors and
cytokines that will modulate the immune response and by inhibiting glutamate toxicity
and promoting angiogenesis.72
The goals of using cellular therapy for SCI include “to bridge any cysts or cavities, to
replace dead cells, and to generate a favorable environment for axon regeneration”.73
Different cell types have been used in preclinical models for SCI besides MSC and HSC;
as described in the previous sections, these have also included Schwann cells (SC),
olfactory ensheathing cells (OEC), neural stem/progenitor cells (NSPC) and faterestricted neural and glial precursors.74 While the exact mechanisms are not completely
understood, some of the trophic effects reported following transplantation after SCI
include: a decrease in macrophages and pro-inflammatory cytokines in some cases, and
in others a change in macrophage phenotype and function, in the form of an increase in
M2 macrophages that could promote neuroprotection and axon regeneration.19
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Recent and on-going Phase I and Phase II clinical trials for SCI include transplantation of
MSC,75 HSC,76 OEC,77 and macrophages,78 to determine feasibility and safety.19 There
are still many important, unresolved questions about the best strategies for stem cell
therapy. For example: what is the optimal cell dose? what is the best route for delivery of
stem cells? where do the cells go after their administration? how long do cells remain at
the transplant site? do cells migrate away from the transplant or target sites within the
CNS or to other tissues in the body? And what is their long-term safety? In order to better
understand the fate of administered stem cells and to develop and optimize stem cell
therapy protocols, methods are needed to allow for in vivo monitoring of the cells over
time.79,

80

The focus of this thesis is on the use of MRI as a method for in vivo cell

tracking.

1.4 Magnetic Resonance Imaging (MRI)
MRI is a powerful technique that provides excellent soft tissue contrast and highresolution images. As the human body has a high water (H20) content, traditional MRI
focuses on protons, since a 1H nucleus has a single proton. Even though there are other
elements that can be imaged with MRI, this thesis focuses on proton imaging. The most
important natural properties of 1H for MRI, which will be used in the next sub-sections,
are proton density (PD), which is the number of 1H atoms per unit volume, and two
characteristic times: T1, which is called the spin-lattice relaxation time and T2, the spinspin relaxation time.81

1.4.1

Nuclear Magnetic Resonance (NMR)

Atomic nuclei have four physical properties: mass, electric charge, magnetism and ‘spin’,
an intrinsic angular momentum, which comes in ½ multiples that can be + or - with 1H
having a spin of ½.82 Once these nuclei are placed in the presence of an external magnetic
field (B0), these momentums or spins will tend to align with it, creating a net magnetic
moment. The gyromagnetic ratio is a constant for each nucleus that represents the ratio of
its magnetic dipole moment to its angular momentum.81 1H has a gyromagnetic ratio of:
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𝛾
𝑀𝐻𝑧
= 42.57
2𝜋
𝑇
As they can’t completely align with B0, the protons will experiment a torque that makes
them precess about B0 at the Larmor frequency:
𝜔! = 𝛾𝐵!
In the presence of B0 a net magnetization moment is produced, as not all protons will
align in the same direction (parallel) as B0, some will align in opposite direction
(antiparallel). Because the parallel direction requires less energy, there will be a greater
fraction of the protons which are aligned in the parallel direction with B0 generating an
equilibrium nuclear magnetization (M0) proportional to B0.83 For 1H M0 will be:
!

𝜌𝛾 ! ℏ 𝐵!
𝑀! =
4𝑘𝑇
where ρ is the density of protons, ħ is Planck‘s constant divided by 2π, k is Boltzmann’s
constant and T is absolute temperature.
Using these NMR principles a sample dependent signal can be generated. This process
can be broadly described in four steps:
1) Place sample in the magnet, where there is a constant magnetic field producing a
an equilibrium magnetization along B0 described by
𝑀! = 𝑀! (1 − 𝑒

!!

!! )

T1 is the spin-lattice relaxation time, a time constant to develop longitudinal
magnetization (Mz). T1 is tissue specific and B0 dependent. When the sample is
initially placed in the magnet, before any excitation, Mz=M0 after ~5T1.
2) Excite the system by applying a time-varying magnetic field (B1) perpendicular to
B0 using a short radiofrequency (RF) excitation pulse, in order to ‘tip’ the spins
around that new magnetic field.
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3) Wait and receive. Once B1 is turned off, the spins will be precessing around a
transverse plane Mxy generating an electromagnetic field in a receiving RF coil.
As the protons return to equilibrium, the magnetization that had been induced on
the transverse plane (Mxy) by B1 starts decreasing, decaying at a rate of:
𝑀!" = 𝑀! 𝑒

!!

!!

Where T2 is the transverse or spin-spin relaxation time, a time constant that
describes the decay of the transverse magnetization (Mxy), and is tissue specific.
4) Analyze data. As a receiving RF coil experiences an electromagnetic field, a
signal from the sample is measured and a Fourier transform is then applied to find
the frequency components of the measured signal.

1.4.2

MRI Basics

MRI uses those NMR principles to generate a signal that can be measured to produce an
image. As mentioned above, T1 and T2 are time constants specific to each tissue so, in
MRI, each tissue will have different signal intensity in an image due to T1 and T2
differences and due to their PD. In order to generate an image from those measured
signals, the location of each point in the sample or tissue generating a signal needs to be
spatially encoded. Gradient coils are used to linearly vary the static magnetic field so that
the nuclei will precess at slightly different frequencies, which can then be used to
distinguish different positions in space.81

1.4.3

Pulse Sequences

There are different pulse sequences used to produce MRI images. As mentioned in the
previous section, Mxy is measured. However, if only one RF excitation pulse was applied
and we waited indefinitely, Mxy would only decay to zero and that would be the end of
the signal. In MRI pulse sequences are used to control Mxy by applying different RF and
gradient pulses so that, instead of always decaying, Mxy can be dephased and rephased
according to the pulse sequences. The rephasing period effectively creates a signal echo,
where the signal is measured.81 The echo time (TE) describes the time from the RF
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excitation to the maximum echo, when the signal is read. The repetition time (TR)
describes the time between each excitation. In general, pulse sequences can be divided in
spin echo (SE) and gradient echo (GE).

1.4.3.1

Spin-Echo (SE)

In the case of the SE sequence, a 90° RF pulse is applied and the spins are allowed to
dephase around the transverse plane (xy) for a certain time before a 180° RF pulse is
applied that will rephase the spins. Different contrast can be acquired with SE sequences
that will depend in TE and TR:81
TE
Short (<40ms) Long (>75ms)
Short (<750ms)

T1-weighted

------

Long (>1500ms)

PD-weighted

T2-weighted

TR

While SE is a basic pulse sequence, other sequences based on it have been developed for
faster imaging with dominant contrast, these include:
•

T1-weighted: inversion recovery (IR), fluid attenuated inversion recovery
(FLAIR), and short TI inversion recovery (STIR)

•

T2-weighted: turbo/fast SE (FSE), turbo gradient and SE (GRASE), Single-shot
FSE (SSFSE) or Half Fourier single-shot turbo SE (HASTE), and SE-echo planar
imaging (SE-EPI).81

1.4.3.2

Gradient-Echo (GE)

A GE sequence will also start with an RF pulse, but this flip angle (α) will be less than
90°, which will allow for faster imaging since less time is required for protons to return to
equilibrium. In this case, instead of using a second 180° RF pulse to generate the echo, a
negative gradient will help the protons rephase, but because this will only account for the
gradient effects, it will not account for the dephasing due to local inhomogeneities in the
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magnetic field, making GE sequences sensitive to T2* (a spin-spin relaxation time that
includes contributions from molecular interactions as well as inhomogeneities in the
magnetic field) effects. Again contrast will depend on imaging parameters:81
TE
Short (<15ms) Long (>30ms)
Small (<40°ms)

PD-weighted

T2*-weighted

Large (>50°ms)

T1-weighted

------

α

GE sequences are ideal for 3D due to their short TR, though they also are advantageous
in 2D for dynamic enhancement and breath-hold studies. While GE is the other basic
pulse sequence, additional sequences have been developed. GE sequences can be
categorized according to their dominant contrast, these include:
•

T1-weighted: spoiled GE, magnetization prepared rapid acquisition by gradient
echo (MP-RAGE), turbo fast low angle shot (Turbo-FLASH), and multi-shot EPI,
GE-EPI

•

T2/T1-weighted: fully balanced GE and balanced steady state free precession
(bSSFP)

•

T2- or T2*-weighted: SSFP and double echo steady state (DESS)81

While they are loosely classified in this way, there can be some overlap.

1.4.3.3

Balanced Steady State Free Precession (bSSFP)

In this thesis we use the bSSFP imaging sequence. While this pulse sequence was
described over half a century ago84 it only has become practical to use in the last decade
or so. bSSFP had been limited by banding artifacts, which appear as bands of low signal
across the images. These bands are worst at areas with substantial magnetic field
inhomogeneity such as at air-tissue interfaces. In order to minimize this banding, a very
short TR and the best possible shimming are required.85 Technological advances have
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improved MRI hardware, including faster gradient amplifiers and more homogeneous B0,
which have resulted in more robust scanners that allow shorter TR times and have
substantially decreased inhomogeneities.86,

87

As advances are made in MRI, different

vendors will use their own names and acronyms for products based on the same concepts;
bSSFP is also known as True-FISP (Siemens) and FIESTA (Fast imaging employing
steady state acquisition, GE) but should not be confused with the other rapid SSFP GE
sequences that are not balanced. The difference between bSSFP and the other fast GE
sequences is a different gradient pattern.

Figure 1.6: bSSFP pulse sequence diagram. RF: radiofrequency pulse, GSS: Slice select
gradient, GPE: Phase encode gradient, GFE: Frequency encode gradient.88
In bSSFP a preparation negative gradient is applied within each TR so that the gradient
dephasing between each excitation is zero. Since the negative gradient will only refocus
the proton dephasing due to the positive gradient and will not compensate for
inhomogeneities in B0 or spin-spin interactions, bSSFP will be sensitive to T2* effects.
bSSFP has a complex contrast, it is T2/T1-weighted for an optimal α, which can be
calculated from:88
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One of the characteristics of bSSFP is that it has “the highest possible signal-to-noise
(SNR) ratio per unit time”.86 Assuming TR<<T1,T2 the on-resonance signal intensity can
be expressed as:88
𝑀!! ≃ 𝑀!

𝑠𝑖𝑛 ∝
!

1 + 𝑐𝑜𝑠 ∝ +(1 − 𝑐𝑜𝑠 ∝)( ! )
!!

Using an optimal α then the on-resonance signal intensity can be expressed as:88
1
𝑇!
𝑀!! ≃ 𝑀!
2
𝑇!
So for tissues where T2≈T1, and with a high α (70°-90°) Mss approaches half of M0.86
bSSFP has been used for clinical applications showing that the speed and T2/T1 contrast
is valuable for cardiac and vascular imaging, where the T2/T1 ratio of blood and
surrounding tissues is significantly different.89,

90

In the field of cellular MRI, the

sensitivity of bSSFP to inhomogeneities has made it effective for tracking iron labeled
cells .91-97

1.4.4

Contrast Agents

Contrast agents are chemicals injected into the body in order to alter the relaxation times
of tissues by decreasing T1 or T2, so that as the contrast agent reaches the target (e.g.
tissue or vasculature) the signal is enhanced as either a hyper- or hypo-intensity with the
background tissues remaining the same so that their signal intensity is not altered.81
Contrast agents are typically used to aid in the detection of pathologies by enhancing
their contrast compared to the surrounding tissue.
When placed within a large magnetic field any material, including tissues can become
temporarily magnetized. The degree at which they will do so is called magnetic
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susceptibility (χ), which is a natural property and is different for different materials and
tissues: water is slightly diamagnetic (χ<0), air and dense bone have almost zero
susceptibility, though only vacuum is nonmagnetic (χ=0). The ensuing inhomogeneity
will be worse at the edge of two materials with different susceptibilities and in some
circumstances fairly severe local inhomogeneities may result.83 Materials can be
classified in four groups from less to more susceptibility:
•

Diamagnetic materials, with weak susceptibilities that may in fact cause an
internal field opposite to B0 (χ<0); most body tissues fall within this range.

•

Paramagnetic materials, which have a stronger susceptibility causing an
internal field in the same direction as B0 (χ>0); examples include gadolinium,
deoxy-hemoglobin and met-hemoglobin.

•

Superparamagnetic materials include iron oxide particles, ferritin and
hemosiderin.

•

Ferromagnetic materials are strongly magnetized that experience a large force
in the presence of B0; examples include metal alloys containing iron, nickel and
cobalt.81

1.4.4.1

T1 Shortening Agents

T1 shortening agents are generally based on gadolinium (Gd). Because by itself the Gd
ion is toxic, it is chelated to a ligand such as diethylene-triamine penta-acetic acid
(DTPA, as in Magnevist® by Schering) to isolate it from the body. Gd-based contrast
agents are delivered i.v., usually by bolus injection and will shorten T1 and T2, in the
tissues where it accumulates. However, at the low doses used clinically, the effect on T1
is much larger. In the clinic typically T1-weighted images are acquired before and after
the administration of a Gd agent and in the post-Gd images the signal in areas where Gd
accumulates becomes hyper-intense. Gd-based agents are generally excreted renally and
will be cleared in about 24hrs. Gd-based agents have been widely used for cancer
detection,98 brain imaging,99 and heart disease.100
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1.4.4.2

T2 Shortening Agents

T2 shortening agents are most often based on superparamagnetic iron oxide (SPIO)
particles. Iron contrast agents also affect T1 and T2, though in this case the effect is more
pronounced on T2, and thus it is usually visualized in T2- or T2*-weighted images.81 As
SPIO particles are superparamagnetic with χ>>0 this produces local inhomogeneities by
increasing the dephasing between protons, thus reducing the local T2 and T2*. This
dephasing will make regions where SPIO is present appear as hypo-intense areas and, as
the effect of inhomogeneity is large, it will extend over an area greater than the particle
itself, making it easier to detect.81 This is a called a “blooming effect”.
Clinically, SPIO-based agents are usually delivered by i.v. infusion and the enhancement
lasts hours to days.101 SPIO-based agents are generally excreted through the liver.101 Iron
oxide based contrast agents have been used clinically for liver imaging.102 T2-weighted
images are acquired before and 24 hours after i.v. SPIO administration. Phagocytic
Kupffer cells within the normal reticuloendothelial system (RES) will take up the i.v.
administered iron, causing areas containing Kupffer cells to appear hypo-intense. In liver
lesions, where no Kupffer cells are present, the signal will remain unchanged.
Unfortunately the clinical grade SPIO-based agents have now been withdrawn from the
market.

1.5 Imaging The Spinal Cord Injury
1.5.1

Clinical Use And Clinical Research

Computed tomography (CT) is the standard imaging protocol for SCI.103 MRI is gaining
popularity due to additional value in the cases of SCI without radiographic abnormality104
and due to its high sensitivity to edema, hemorrhage and soft tissue damage, especially
when no fracture occurs. However, it is not yet practical or cost effective across all
institutions.105 Other spinal pathologies that have been observed clinically using MRI
include extended atrophy106 and syringomyelia; thus, when possible and practical, MRI
has shown value for management and prognosis making it the modality of choice.107, 108
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Specialized MRI techniques continue to be developed for SCI assessment. Diffusion
tensor imaging (DTI) has been used to examine SCI in greater detail than through
anatomical MRI by using fractional anisotropy and apparent diffusion coefficients for
nerve fibers tractography and correlating the data from MRI to motor function.109
Susceptibility weighted imaging (SWI) has been used to detect small bleeds in SCI
patients.110 As functional recovery is the goal for SCI management and therapies, tools to
better understand function within the cord are also being developed such as functional
MRI (fMRI), which is used to visualize neural activity and is being developed to monitor
SCI and its responses to treatments.111 All of these MRI techniques were initially
developed to study the brain and the translation to spinal cord imaging has not been
without challenges specific to the cord, such as the relative size of the cord compared to
the brain (as these techniques use large voxel sizes), and motion artifacts from breathing
and CSF pulsation.
In the cellular therapy research setting, MRI has been used to study changes in SCI in
response to stem cell therapy. In a study where patients with a chronic SCI received HSC
by direct transplant and i.v. infusion, MRI was used to exclude patients before the study,
to assess complications following treatment, and to analyze whether there was cord
thickening at the sites of atrophy after the treatment.57 In a different case, where fetal
neural stem cells were transplanted by intracerebellar and intrathecal injections in a
patient with ataxia telangiectasia, MRI was used to assess complications, which included
a tumor in the spine. MRI of the spine was used for tumor monitoring, pre-surgical
planning and follow-up after surgery.44

1.5.2

Rodent MRI Of SCI

As MRI use grows in the clinical setting, so it has in pre-clinical models. In order to
assess potential therapies, it is imperative to be able to monitor the response to treatments
in vivo, with longitudinal studies. Ohta et al. performed the first study where in vivo MRI
findings at 2T were correlated to histological analysis using a cervical compression SCI
rat model. They described areas of signal hypo-intensity in T2-weighted images due to
hemorrhage, and areas of hyper-intensity 4 weeks after the injury that reflected edema,
gliosis and cavity formation.112 Rodents are common models in SCI research; however,
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their size relative to a human (e.g. 25g mouse, 300g rat, 80kg human) means that imaging
technology needs to be able to achieve higher resolution in order to get good tissue
visualization. In rat models, as animal-dedicated scanners operating at higher magnetic
fields have become available they have been increasingly used for SCI research (e.g.
7T113, 114). MRI has been used to compare SCI severities in a rat contusion model at 4.7T
by assessing edema and lesion length.115 High-field MRI in SCI rat models has also been
used to study syringomyelia at 9.4T,116 and to study cyst formation, hemosiderin
deposition, edema and fibroglial scar in a rat contusion model of SCI at 17.6T.117
A recent study by Sandner et al. showed that high-resolution MRI could be performed at
clinical field strengths (3T) in a rat contusion model allowing for GM/WM differentiation
in the uninjured cord and hemorrhage, edema and cyst formation in SCI rats, which were
correlated to histology.118 The authors discuss the advantages of using a clinical scanner,
such as bore size, which they reported allowed for imaging of older and thus bigger rats
without being limited in size, decreased mortality, since it allows for better ventilation,
and availability. This study was followed up by a comprehensive description of the
imaging techniques used to study CNS pathologies, including SCI, in rat models at 3T.119
Additional imaging techniques continue to be developed for SCI assessment, including
manganese enhanced imaging,120 magnetization transfer,121 DTI,114, 122 and fMRI.123
Recently a comparison was made between mouse and rat SCI models using MRI (7T).124
In vivo imaging of experimental disease models in the mouse spinal cord is particularly
difficult because of the very small size of the cord itself (1.5mm2 in x-sec area)28 and the
extreme curvature, which becomes more pronounced with SCI, besides the challenges
associated with imaging SCI mice in vivo over time. These challenges include
diminished thermal regulation, decreased breathing capacity, and deficits in
cardiovascular function.125 In fact there have not been nearly as many studies in mouse
SCI models as in rats especially with non-contrast enhanced anatomical MRI. There are
only a few SCI mouse MRI in vivo studies using ultra-high magnetic fields (9.4T),126
DTI (4.7 T127 and 9.4T128), manganese enhancement,129 and gadolinium enhancement at
7T.124 More mouse cord studies have been done ex vivo130, 131 and only recently has the
cord being imaged in vivo at a clinical field strength (1.5T).132

24

1.6 Cellular MRI
Cellular MRI is a relatively young field of imaging which uses high resolution MRI along
with contrast agents to study cellular events. The first studies appeared in the 90’s where
iron-based contrast agents started to be used to label cells and be visualized through
negative contrast enhancement in MRI133-135 and showed at those early stages great
promise for future use of cellular MRI in disease and therapy. Iron oxide particles have
been the most widely used contrast agent to label cells for detection by MRI.

1.6.1

Cell Labeling

In order to be able to detect cells with MRI, they must be labeled with a contrast agent.
Most studies use one of two ways to label cells with iron particles, in situ or in vitro. In
situ labeling, also called ‘active labeling’, is performed by injecting iron particles into the
bloodstream and is most often used to target circulating immune cells, or immune cells in
inflamed tissues, which can phagocytose the particles.
In vitro cell labeling is used mainly for cell tracking. To label cells in vitro the cells are
co-incubated with the iron particles. Many cell types will readily take up iron particles
by simple co-incubation. For example, macrophages, cancer cells and stem cells are
relatively easy to label. Other cells, especially non-adherent cell types, are more difficult
to label and require specialized techniques. Various methods have been developed to
enhance the amount of iron taken up by cells. The use of transfection agents, such as
poly-L-lysine, protamine sulfate, and lipofectamine, was one of the early methods
demonstrated to improve uptake of iron particles.136 These compounds are positively
charged and form complexes with the negatively charged iron particles through
electrostatic interactions upon mixing prior to cell labeling. These complexes facilitate
internalization of the iron particles into the cell membrane during labeling incubation.101
One of the concerns in cell labeling is the fact that most protocols require long incubation
periods, usually overnight, so a recent study assessed commercially available NH2
functionalized iron particles and showed improved labeling efficiency in less than 4hrs in
mouse embryonic fibroblasts, rat MSC, and rat BM-derived macrophages.137
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Another method to improve uptake of iron particles is electroporation, also called
magnetoelectroporation.136,

138, 139

In electroporation the cell membrane is temporarily

disrupted allowing particles to move into the cell.

Walczak et al. developed this

technique and used it to label neural mouse cells and human and rat MSC with iron
internalization comparable to that achieved by traditional transfection agents without
affecting cell viability, proliferation or differentiation capabilities, although labeling by
electroporation requires careful optimization of parameters to avoid cell death.138 This
technique has also been applied for leukocyte labeling.139 Other methods continue to be
studied and developed to improve cell-labeling efficiency, like the use of magnetic fields
and cell penetrating peptides.140

1.6.2
1.6.2.1

Iron Particles
Ultra-Small Superparamagnetic Iron Oxides (USPIO)

Iron particles have traditionally been classified according to size. Ultra-small superparamagnetic iron oxides (USPIO) are particles with an iron core of approximately 5nm
of maghemite (γFe2O3) and magnetite (Fe3O4) and a coating that can be made of dextran,
citrate, carboxylmethyl-dextran, carboxydextran, or pegylated starch that brings the
particle’s hydrodynamic diameter to roughly 10-50nm in size.141 Because of their small
size these particles have a long circulation time and have been useful for labeling cells in
situ in many animal models of inflammatory disease.142-145 USPIO has been used for
atherosclerotic plaque models146 and continues to be developed for enzymatic
activation.147 USPIO has also been used clinically for carotid artery plaque148 and lymph
node imaging.149 Deserno et al. described how after i.v. injection, macrophages will take
up the USPIO and carry them to the interstitial space, through the lymph vessels to the
lymph nodes. If the tissue is healthy, USPIO-carrying macrophages will show up as areas
of hypo-intensity, but in cancerous areas, where cancer cells will not take the USPIO and
macrophages will not be able to occupy the same space, areas will seem brighter against
the now darker background. This technique has been used for prostate, rectal, bladder,
breast, head and neck cancer imaging.150 While USPIO has been used primarily for in situ
labeling, it has also been used for in vitro cell labeling and cell tracking. For example, to
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track human adipose derived stem cells in a bone tissue engineering mouse model151 and
human umbilical cord-derived MSC in the intact rodent brain.152

1.6.2.2

Superparamagnetic Iron Oxides (SPIO)

Standard superparamagnetic iron oxide particles (SPIO) have a similar core to USPIO,
although slightly larger (7nm) coated with dextran, carboxydextran, starch, albumin or
silicon153 with a hydrodynamic diameter of roughly 60-150nm.154 SPIO are the most
commonly used iron agents for cellular MRI. They are used for both in situ and in vitro
cell labeling. Using in situ labeling, the earliest method for cell tracking, SPIO has been
used to detect and monitor inflammatory cells in animal models of multiple sclerosis,155
SCI,96 arthritis,156 tissue rejection157 and atherosclerosis.158 The i.v. administration of
SPIO was used extensively for clinical liver imaging159, 160 and it has also been used in
clinical studies of atherosclerosis.161 In vitro labeling of cells with SPIO has been used
for cell tracking in different animal models, for example to study distribution after i.v.
injection of HSC,162 tissue rejection,163, 164 Parkinson’s disease models,165 and dendritic
cell (DC) migration.166 SPIO has been used clinically for cell tracking in patients with
melanoma (Netherlands),167 brain trauma (China),168 hypoxic brain injury (Poland),169
diabetes (Switzerland170 and Czech Republic171), and one study that included multiple
sclerosis (MS) and amyotrophic lateral sclerosis (ALS) (Israel).172 It should be noted that
none of these studies have been performed in North America.

1.6.2.3

Micron Sized Iron Oxides (MPIO)

Micron-sized iron oxide agents (MPIO) are the largest particles. These are basically
plastic beads that were originally developed for cell sorting. One type, Bangs beads
(Bangs Laboratories, Fishers, IN) have a magnetite (Fe3O4) core encapsulated in a divinyl
benzene/styrene polymer with a hydrodynamic diameter of >1µm (0.9-8 µm). MPIO
available from Chemicell have a core of 100-200nm of maghemite (γFe2O3) with a silica
coating that brings its hydrodynamic diameter to 0.5µm, 0.75µm or 1.0µm (chemicell,
Berlin, Germany). MPIO can come dyed with a fluorescent tag and are inert.173 Both
phagocytic and non-phagocytic cells readily endocytose the particles without the use of
transfection agents and result in a higher iron content compared to cells labeled with
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USPIO or SPIO.154 Because they are not biodegradable, MPIO have only been used in
preclinical studies and only by a handful of imaging researchers.
MPIO have typically been used for prelabeling of cells prior to their injection or
implantation. Shapiro et al. showed that a single mouse hepatocyte labeled with MPIO
could be detected in vivo with MRI. Other cells have been labeled in vitro with MPIO
such as T-cells174 and macrophages.175 Our group has used MPIO for several years for in
vitro cell labeling for tracking in models of glioma,97, 176 melanoma,177 metastasis,178, 179
and DC migration.91 Recently Wu et al. have demonstrated that MPIO can also be used to
label cells in situ in a rat cardiac rejection model180 and Foley et al. used the same
technique for macrophage labeling in a mouse traumatic brain injury.181 In a slightly
different approach for in situ labeling, endogenous neural progenitor cells were labeled
by injecting MPIO directly into the lateral ventricle in the rat brain.182, 183

1.6.3

Other Contrast Agents

In recent years, Gd-based agents are being explored for cell tracking.184-187 The potential
advantage of using Gd agents is the generation of positive contrast, rather than signal
void, which addresses issues related to other sources of signal loss in MR images that can
confuse image interpretation. However, the relaxivities of most Gd-based agents are
much lower than iron-based labels and so the sensitivity is not as good and higher
number of cells are needed for detection. Other examples of positive contrast agents
being researched to label cells include manganese188 and fluorine-19 (19F).189

1.6.4

Methods For Assessing Effects of Labeling

It is important to assess cell viability, phenotype and function after in vitro labeling.136, 190
A variety of methods can be used to measure the impact of labeling cells with iron
particles. These include: trypan blue exclusion for viability and cell proliferation by
population doubling time and colony formation. Functionality can be assessed through
many different assays. Examples include the wound-healing (scratch) assay to evaluate
migration;

differentiation

assays

to

assess

osteogenesis,

adipogenesis,

and

chondrogenesis; and gene expression profiling using micro-array analysis and
quantitative polymerase chain reaction.
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The majority of studies have reported no effect on the cells from iron labeling.136, 191, 192
However, Soenen et al. have shown that too much iron will affect the cells by modifying
the actin cytoskeleton which is involved in processes such as proliferation and
apoptosis.193 In a study using USPIO labeled mouse ESC and MSC and rat multipotent
adult progenitor cells Crabbe et al. reported that while differentiation was not affected,
proliferation was changed.190 In another study Kostura et al. reported that SPIO inhibited
differentiation into chondrocytes, but not adipocytes or osteocytes, in human MSC.194 In
SPIO labeled DC, Dekaban et al. reported substantially reduced viability and changes in
cell morphology at concentrations in excess of 400 mg/ml of SPIO. Two recent papers
describe the need for balancing of optimal cell labeling, for enhancing cell detection, and
minimizing impact of iron on cell viability and function.195, 196

1.6.5

Imaging Of Transplanted Cells

MRI provides the opportunity to track these cells in vivo and may provide answers to
matters such as optimal delivery route, overall distribution and trafficking to the organs
of interest. Both iron197 and Gd-based198 agents have been used to image MSC in the
CNS.

1.6.5.1

MRI Of MSC Cellular Therapy In Preclinical Models

There have now been several reports of imaging iron labeled MSC in disease models,
these have included: infarcted heart rat models,199 lung metastasis, where MSC are being
considered for their potential to deliver therapeutic agents,191 and different CNS models
of disease such as middle cerebral artery occlusion, cortical photochemical lesions, and
SCI.197, 200
In SCI models, most cell tracking studies have been performed in rats. A couple of these
imaging studies have come from the Sykova group and were performed on ex vivo cords.
201, 202

They have shown that BM-derived MSC can be visualized as areas of signal loss at

the lesion site at 4-5 weeks after transplant. Dunning et al. have used both SPIO and
MPIO in vivo to label and track SC and OEC for up to 4 weeks in SCI rats. They also
showed by histology that transplanted cells were remyelinating the demyelinated axons,
demonstrating that the labeled cells retained their biological function and that the
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majority of the label had remained within the transplanted cells.203, 204 Lee et al. tracked
SPIO labeled OEC in rat SCI for 2 months and found that MRI was able to show that the
OEC were unable to bridge the transection lesion.205 A couple of recent in vivo cell
tracking studies have used a dual fluorescent/Gd-based label to track MSC in SCI rats
and found that the distribution and migration of labeled MSC in SCI lesions could be
tracked with MRI until 7 days after implantation on one study (though with a significant
decrease in signal intensity after day 3),206 and up to two weeks in another.207 To the best
of our knowledge there are no other published reports on cell tracking in a mouse model
of SCI.

1.6.5.2

MRI Of Cellular Therapy In Clinical Trials

There have been a small number of clinical trials for cell therapy, which have used cell
tracking with MRI. In the first study (Netherlands) De Vries et al.,167 monitored SPIOlabeled DC after their intranodal injection into the lymph nodes of melanoma patients.
While the injections were performed under ultrasound guidance by an experienced
radiologist, MRI revealed that ~50% were failed injections, an important finding in the
field of cell therapy. The other clinical MRI cell tracking studies have been in brain
trauma (China),168 hypoxic brain injury (Poland),169 diabetes (Switzerland170 and Czech
Republic171), MS and ALS (Israel),172 and last, but not least, one study in SCI (Brazil).208
In this study, autologous HSC were labeled in vitro using MPIO coated with a CD34
specific monoclonal antibody and injected in 10 patients with chronic SCI by lumbar
puncture, while 6 patients received free MPIO. MRI showed areas of signal loss 20 days
after transplantation in the patients that received labeled cells but not on the control
patients.
The lack of uniformity in cell types, labeling methods and imaging protocols make it
difficult to compare between studies at this point. Nevertheless, both animal models and
clinical trials have established that the ability to observe the overall distribution at
different time points at the tissue or organ of interest, as well as the overall distribution,
provides important information for cell therapy.
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1.7 Rationale And Objectives
SCI is a complex medical condition with no cure currently available. Cell therapy has
emerged as a promising treatment for SCI due to the potential for MSC to differentiate
into neural cells and, possibly more so, for their potential to exert immunomodulatory
effects and trophic support of endogenous cells. Determining the fate of transplanted
stem cells in vivo will be a critical component of trials for optimizing cellular therapies.
MRI is capable of providing the spatial resolution and cell detection required to
noninvasively monitor cells administered in SCI.
Inflammation plays an important role in SCI. Macrophages that infiltrate the injured cord
tissue are known to have both beneficial effects, which will promote healing, and
detrimental effects, which will exacerbate the injury. Progress has been made in
understanding some of the mechanisms; however, there is still much to understand about
the specific roles of these cells. Anti-inflammatory treatments aimed at reducing
secondary injury due to inflammation in SCI would benefit tremendously from in vivo
techniques for measuring cell numbers and spatial distribution and for monitoring
changes in these parameters with treatment.
The overall objective of this work was to investigate the use of cellular MRI to assess
experimental SCI in vivo at 3T and to monitor the fate of transplanted MSC and the
inflammatory response to SCI.
Three specific objectives were undertaken.
1. To image the normal mouse spinal cord in vivo using a 3T clinical whole-body
MR system and to monitor the lesion in mouse traumatic spinal cord injury.
(Chapter 2)
2. To apply high-resolution cellular MRI technologies to follow MSC after
transplantation in a traumatic SCI mouse model over time. (Chapter 3)
3. To implement the techniques for imaging the macrophage response in vivo in rat
SCI. (Chapter 4)
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Chapter 2

2

In Vivo Magnetic Resonance Imaging Of Spinal Cord
Injury In The Mouse*
Experimental models of spinal cord injury (SCI) are often performed in rodents with
mouse models being increasingly utilized due to the recent availability of many
interesting and valuable genetically modified mice.1-3 A variety of methods have been
used to generate SCI in mice including clip compression, impactor devices and
transections.4-7 SCI mice display a wound healing process that has not been seen in any
other species.8 Understanding how SCI lesions develop and change over time in the mice
is important for the design of new treatments aimed at promoting regeneration and repair.
Currently, histopathology is the most commonly used method for evaluating
experimental SCI. This traditional method is invasive, usually cross-sectional, labor
intensive and provides only a “snapshot” of the overall pathology, especially for the
spinal cord since it is practically impossible to section and analyze the cord in its entirety.
Experimental studies of SCI would benefit greatly from imaging techniques that allow
monitoring of the SCI dynamically in entire organs or animals.
Magnetic resonance imaging (MRI) has several characteristics that make it effective for
in vivo experimental studies of SCI. MRI can produce images with high spatial resolution
and exquisite soft tissue contrast. Current micro-MRI techniques can achieve in vivo
resolution on the order of tens of micrometers9,

10

and even higher resolutions, below

5µm, have been reported in polymer bead phantoms11 and for imaging single cells in gel
and water.12 MRI is non-invasive, nondestructive and three-dimensional (3D). Unlike
histological analyses, MRI can provide a more dynamic view of changing pathology and
cellular events in vivo.13-15

*
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In vivo MRI of experimental SCI is difficult, however, because of the very small size of
the cord itself (1.5mm2 in cross-sectional area at the thoracic level8), the extreme
curvature and the challenges associated with repeated imaging of diseased mice in vivo.
As a result, there are only a few published reports of in vivo MRI studies of mouse cord
injuries. In vivo anatomical imaging of the injured mouse cord has been accomplished
using implantable radiofrequency coils,16 high field (9.4T, 11.75T), dedicated animal
MRI scanners,17, 18 and manganese enhancement.19
Cellular MRI is a newly emerging field of MR research that allows the “non-invasive and
repetitive imaging of targeted cells and cellular processes in living organisms”.20 Cellular
MRI requires that cells be labeled with MR contrast material to make them distinct from
the surrounding tissues with magnetic iron nanoparticles being the preferred material.21, 22
Areas containing iron-labeled cells appear as regions of signal loss on MR images,
creating negative contrast.23, 24 In experimental cellular MRI, cells are typically loaded
with magnetic particles prior to their injection or implantation. The resulting signal
hypo-intensities can be tracked in vivo providing information about the presence, location
and migration of the iron-labeled cells.25-28 Various cell types have been tracked in vivo
over several weeks and multiple cell divisions and with minimal impact on cell
function.29-34 In 2006 we showed, for the first time, that even single iron-labeled cells can
be visualized in vivo using MRI.35
The use of cellular MRI to track transplanted stem cells has become a key area of cellular
imaging research.36-39 Research aimed at visualizing transplanted cells in experimental
diseases of the central nervous system (CNS) has provided good examples for the use of
these tools. Some examples have included imaging of: iron-labeled neural stem cells
transplanted into embryonic mouse brain,40 iron-labeled oligodendroglial progenitors
transplanted into the ventricles of neonatal, myelin deficient rat brain,41 iron-labeled glial
precursor cells transplanted as neurospheres into the ventricles of rats with experimental
autoimmune encephalomyelitis,42 iron-labeled neural progenitor cells transplanted into
the striatum of Parkinsonian mice43 and hematopoeitic progenitor and multipotent
mesenchymal stromal cells (MSC) labeled with micron-sized iron oxide particles
(MPIO).44 So far, nearly all studies have been of the ‘proof-of-principle’ type,
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demonstrating that different types of iron nanoparticles and labeling strategies are useful
for the non-invasive MR tracking of transplanted cells. There are no reports of in vivo
cellular MRI being used to image the injured mouse spinal cord after transplantation of
iron-labeled cells. Only a few studies have demonstrated the use of cellular imaging to
monitor cell transplants after SCI and these have all been in rat models.45-47
In this paper we demonstrated the use of high resolution MRI for the longitudinal
anatomical imaging of SCI in the mouse. We also demonstrated, for the first time, the
application of cellular MRI for the in vivo tracking of transplanted stem cells in the
injured mouse spinal cord.

2.1 Methods
2.1.1

Animal Model

All protocols for these experiments were approved by the University of Western Ontario
Animal Care Committee in accordance with the policies established by the Canadian
Council on Animal Care.
For optimization of the MRI protocol healthy, uninjured (n=11) and SCI (n=14) C57/Bl6
mice (Charles River Laboratories, W ilmington, MA , USA ) were used. Briefly, SCI was
induced in 20-25g female mice at the level of the 4th thoracic (T4) vertebrae using a clip
compression model.6 Mice were premedicated with atropine sulfate [0.05 mg/kg
subcutaneously (s.c.); MTC Pharmaceuticals, Cambridge, ON, Canada] and placed on a
heating pad to maintain body temperature. Surgical anesthesia was achieved using
isoflurane USP (1.5% to induce and 1.25% to maintain; A bbott Laboratories, SaintLaurent, QC, Canada) in oxygen at a rate of 1 l/min, delivered through a nose cone. With
the assistance of a surgical microscope, a laminectomy was performed to expose the T4
segment of the spinal cord, as described by Joshi and Fehlings, and a FEJOTATM clip was
used to compress the cord extradurally for 60 seconds, with a force of 8g. The muscles
and the skin were closed with 4-0 Vicryl and the animals were allowed to recover under a
heating lamp and then on a heated water pad. All animals were treated with
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buprenorphine (0.1 mg/kg s.c.; Temgesic, Schering-Plough, Hertfordshire, UK) as
needed and 5 mg/kg of Baytril (Bayer, Toronton, ON, Canada) and 0.5ml (1ml on the day
of surgery) of 0.9% saline twice daily for 3 days. Bladders were voided twice daily by
manual compression.

2.1.2

Transplantation Model

Whole bone marrow was acquired from the femurs of 3-6 month old mice and plated
onto T-25cm2 tissue culture flasks (BD Falcon™, Mississauga, ON, Canada) by
adherence. 5ml of Dulbecco/Vogt modified Eagle's minimal essential medium (DMEM)
with 10% fetal bovine serum (FBS), 2nM L-glutamine, 100 units/ml penicillin and
100 µg/ml streptomycin were added and cells were kept at 37ºC in 5% carbon dioxide.
Non-adherent cells were removed and cells were passaged with fresh medium (1:3
dilution) until reaching 80% confluency. MSC were characterized by flow cytometry
using antibodies raised against a battery of markers at passage four, including c-kit,
CD11b, CD31, CD34, CD45 and relative isotype controls.
In order to be able to detect the donor MSC with MRI they were labeled with iron.48-50
The cells were washed with Hank's balanced salt solution (HBSS; GIBCO®,
Invitrogen™, Burlington, ON, Canada) and incubated for 24hrs at 37ºC in 10ml of fresh
DMEM containing 10µl of magnetic silica particles (SiMAG, 0.75µm; chemicell, Berlin,
Germany). The trypan blue exclusion and plating efficiency assays were performed to
examine potential effects of iron oxide particles on cell functions and viability.
At day 2 post SCI, 3 x 104 MSC were transplanted into the injured mice. An intra-spinal
transplant was performed by excising the dura at the epicenter of the SCI (T4 level).
Using a spinal stereotaxic frame, 3x104 cells in 3µl of saline were transplanted with a
glass pipette (tip diameter=100µm) configured to a 10µl Hamilton syringe51 (n=13
received labeled cells, n=3 received unlabeled cells).

2.1.3

Magnetic Resonance Imaging

Imaging was performed using a 3 Tesla (3T) GE whole-body MR scanner (MR Signa®
Excite™, GE Healthcare, Milwaukee, W I, USA ) using a custom-built gradient coil (inner
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diameter=17.5cm, maximum gradient strength=500 mT/m, and peak slew rate=3000
T/m/sec). Mice were anesthetized with isoflurane (2%) and placed on a custom-built
plastic sled to permit careful and reproducible positioning to allow sagittal imaging of the
cord. The sled was positioned within a custom-built solenoid radiofrequency (RF) coil
(the antenna of the MR system), which is 4cm in length and 3cm in diameter, allowing
for the acquisition of whole mouse body images. The lower part of the body and tail were
wrapped using gauze to maintain body temperature.52 Mice were scanned using a 3D
balanced steady state free precession (bSSFP) pulse sequence (3D-FIESTA; GE Medical
Systems, Milwaukee, W I, USA ; TR/TE=3.8/1.8ms, α=25º) at a 200µm isotropic
resolution with 16 NEX and employing RF phase cycling. Acquisition time was 31min.
Mice recovered under a heating lamp. SCI mice were imaged weekly for up to 6 weeks.
Transplanted mice were imaged at day 2 after the transplant and then weekly for up to 6
weeks.

2.1.4

Image Analysis

Image quality was assessed by calculating the image signal to noise ratio (SNR). The
mean signal intensity in a region of interest in the spinal cord was divided by the standard
deviation of the background noise in air. Images of injured cords were assessed for
changes in signal intensity at the lesion epicenter. 3D image data allowed for an analysis
of patterns of image contrast in all orientations. Images of transplanted mice were
assessed for regions of signal loss due to the presence of iron-labeled cells. The regions
of interest were measured by manual segmentation using the open-source imaging
software OsiriX.53

2.1.5

Histopathology

After the final imaging session the mice were induced with deep anesthesia, and
transcardially perfused with 4% paraformaldehyde (PFA) in 0.1M phosphate buffer. The
spinal cords were removed and placed in phosphate buffer containing 20% sucrose at 4ºC
overnight. Cord tissue was sagittally sectioned on a cryostat set at 16µm. The sections
were serially collected on gelatine-coated glass slides and subsequently stained with
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standard hematoxylin and eosin (H&E) techniques for visualization of the cord and lesion
morphology, and with Perls’ Prussian blue (PPB), for visualization of the iron particles.

2.2 Results
2.2.1

Anatomical Imaging

3D-bSSFP mouse cord images were obtained at 3T with a cord SNR of approximately
50. Representative in vivo images from a control, intact mouse are shown in Figure 2.1.

Figure 2.1: In vivo high-resolution (200µm isotropic) MR images of a mouse spinal
cord using 3D–bSSFP (TR/TE=3.8/1.8ms). (a) Sagittal view of a healthy uninjured
mouse in the prone position with the head to the right. Scale bar=5mm. (b) Cord axial
views can be reconstructed by digital reslicing of the 3D image data, in a tilted plane
(dashed line in a) to compensate for the natural curvature of the mouse spine. Scale bar=2
mm.
In all SCI mice the injury appeared as a region of heterogeneous signal, which included
areas of both signal hyper-intensity and signal loss. Figure 2.2 shows four images,
acquired at different time points, from a representative SCI mouse; the long arrows
indicate the lesion epicenter. In this mouse the lesion appears subtle for up to 1 week post
SCI (Fig. 2.2a). Over time, as the lesion evolved, signal loss became more apparent at
the epicenter. At 4 weeks post SCI (Fig. 2.2c) a more distinct region of signal loss at the
lesion epicenter defines the lesion more clearly. The signal loss was evident in the
majority of mice by 2 weeks post SCI, and in all cases persisted for the 6 weeks of the
study. In addition, the area surrounding the cord tissue, which contains the cerebrospinal
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fluid (CSF), which appears very bright in the images (short arrows, Fig. 2.2b), was larger
in all SCI mice compared to control, uninjured mice.

Figure 2.2: Representative in vivo sagittal spinal cord images. Here the same animal is
shown at different time points after SCI: (a) 1 week, (b) 2 weeks, (c) 4 weeks, and (d) 6
weeks. The epicenter of the injury (long arrows) appears as a region of heterogeneous
signal at 1 week. By 4 weeks, a region of signal loss appears obvious at the lesion
epicenter. The area surrounding the cord and containing the CSF, which appears with
high signal intensity (short arrows), is enlarged in SCI mice.
Of particular interest was the observation of fluid filled lesions in 3/16 mice. These cystlike lesions were rostral to the epicenter of the injury (up to 8mm away), they were first
observed as early as 2 weeks post SCI, and they increased in size with time. Figure 2.3
shows representative sagittal (Fig. 2.3a) and axial (Fig. 2.3b) images of a SCI mouse cord
at 3 weeks post SCI with this fluid filled lesion, in this image the lesion was 0.73mm3.
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This lesion was first observed at 2 weeks and measured 0.36mm3. By the end of the
study, at 6 weeks, the lesion measured 1.05mm3. Cyst-like lesions in the other two
animals also increased in volume over time.

Figure 2.3: A fluid-filled, cyst-like lesion is visible rostral to the lesion epicenter. The
cyst volume increased in size over time from when it was first observed at 2 weeks (a,
arrow, 0.36mm3) to the end of the study at 6 weeks (b, 1.05mm3). (c) The axial view is
shown at the level indicated by the dashed line in b.

2.2.2

Cellular Imaging of Transplanted MSC

The trypan blue exclusion assay showed that 100% of both labeled and unlabeled cells
were viable after harvesting. Plating efficiency results showed for labeled and unlabeled
cells an efficiency of 74% and 95% respectively (each from an average of six plates).
The average iron content was found to be 83.65pg Fe/cell.
Representative images of an injured mouse transplanted with iron-labeled MSC are
shown in Figure 2.4. A large region of signal loss was observed at the site of the
transplant on day 2 post transplant (arrows, Fig. 2.4a). The region of signal loss persisted
over the 6 weeks of the experiment but diminished in size with time. Similar observations
were made in 9 of the 13 SCI mice that received iron-labeled MSC transplants. The total
void volume measured on the first scanning session was different for each animal, despite
having implanted the same numbers of MSC, likely due to both small differences in the
implantation procedure and differences in cell survival between the implant and the first
scan. The 3D image data allowed for image rendering and 3D reconstruction. A single
frame from the reconstructed image data is shown in Figure 2.4d and clearly depicts the
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extreme curvature of the injured cord and the location of the transplanted MSC (red) at 1week post transplant.

Figure 2.4: Representative in vivo images of the injured mouse spinal cord after
transplantation of iron-labeled MSC. A large region of signal loss (arrows) is easily
visualized at the site of transplantation and diminishes over time during 6 weeks of
scanning post-transplant (shown counterclockwise). The volume of the region of signal
void for this representative mouse was 6.76mm3 on day 2 post-transplant (a), 5.47mm3
on week 2 (b), and 4.21mm3 on week 5 post-transplant (c). (d) A single still frame of the
same mouse spinal cord is shown after segmentation and 3D rendering of week 1 image
data (6.12mm3). The site of transplantation is shown in red. The mouse body has been
segmented out of the image data to allow better visualization of the cord.
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Measurements of the volume of the signal loss in the cord showed a reduction with time
in all animals (Figure 2.5).
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1

Figure 2.5: Volume of the region of signal loss in the cord for all mice. Each symbol
represents one of the nine mice that showed regions of signal loss following the
transplant of labeled MSC.
In Figure 2.6 PPB staining shows iron labeled cells in the injured mouse cord at 6 weeks
post cell implantation. At the lesion epicenter (Fig. 2.6 a&b) there are greater numbers of
iron positive cells (blue), though the cells are not limited to the epicenter and can be seen
away from the epicenter at a lower concentration. Figure 2.6 c&d show iron labeled cells
in a section approximately 1mm caudal from the lesion epicenter.
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Figure 2.6: Staining with PPB showed iron-labeled cells at 6 weeks post-transplant. At
the lesion epicenter, there is a higher concentration of iron-positive cells (blue, 40x
magnification, a,b). Iron-labeled cells are also present, at a lower concentration, 1mm
caudal from the lesion epicenter (10x magnification, c). The region of interest outlined in
c is shown in d at higher magnification, iron is intracellular (d).
Figure 2.7 shows representative images of the cord in a SCI mouse that received a
transplant of unlabeled MSC. These images appeared very similar to the images of SCI
mice that received no cell transplant (shown in Figure 2.2). The lesion is subtle in images
acquired during the first week post transplant with small regions of signal loss developed
by 3 weeks post transplant.
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Figure 2.7: In vivo images of the injured mouse spinal cord after transplantation of
unlabeled MSC. As in SCI mice that received no transplant, the lesion epicenter is not
obvious in the first week post SCI. (a&b) Images acquired at 2 days and 1 week posttransplant (epicenter indicated by arrows). (c) At 3 weeks, areas of signal loss are
observed rostral and caudal to the epicenter (arrow). (d) The signal loss in these areas
became even more evident by week 6.

2.3 Discussion
Key to our success was the use of a fast, 3D imaging sequence. The bSSFP sequence is
known to yield a high SNR in short acquisition times and to generate T2/T1 contrast.54, 55
It is also very sensitive to the local magnetic field variations caused by iron particles.
This sensitivity to local field variations has also be known to cause characteristic banding
artifacts56 which become worse with increasing field strength,57 and thus has limited the
application of this imaging sequence for preclinical mouse imaging. We have previously
imaged the mouse brain at 1.5 and 3T with bSSFP.35, 58, 59 Banding artifacts, which were
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pronounced at 3T, were suppressed by the combination of alternating RF phase
acquisitions and sum of squares reconstruction. Recently Miraux et al. showed that this
strategy also allows the application of this sequence for mouse brain imaging at 4.7 and
9.4T.60 The work presented here was the first application of this imaging strategy for
imaging the mouse body, which presents added challenges because there are multiple
additional sources of magnetic field inhomogeneities in the body (air in lungs, intestines,
bone, numerous fat-tissue interfaces) that may disintegrate image quality. bSSFP images
of the injured mouse spinal cord showed a heterogeneous signal at the lesion epicenter
with areas of both signal hyper-intensity and signal hypo-intensity, representing the
mixed pathology present in the injured cord. This is similar to what has been previously
reported by Bilgen et al. in mice with a contusion SCI.18
The areas of signal loss in cord images of mice that did not received a transplant or
received unlabeled MSC may be due to the accumulation of hemosiderin-laden
macrophages, associated with hemorrhage breakdown. Bilgen et al. reported that signal
loss in MR images of the injured rat cord was due to hemorrhage.18 Lee et al. showed that
needle injury to the rat spinal cord during a cell transplantation procedure produced
signal loss in rat cord images that could be attributed to hemosiderin-positive cells.47
Alternatively, signal loss in the SCI lesion may be due to the generation of fibrous
connective tissue which has been shown to fill the lesion site in mice.8 In fact, both of
these pathological processes may be evident in the injured mouse cord and contributing
to signal hypo-intensities.
Whatever the source, signal loss in the images of the injured mouse cord may complicate
the interpretation of images in MRI cell tracking studies which use iron as the cell label
and signal loss as the indicator of cells. Distinguishing hypo-intensities due to ironlabeled cells from other causes of negative image contrast, might be solved by using
positive (gadolinium-based) contrast agents for cell labels.61 The development of new
pulse sequences which generate positive contrast from iron-labeled cells, which is
underway, may also alleviate this concern.62,
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Alternatively one might acquire two

different image contrasts and compare images to differentiate sources of signal loss, as
Kusterman et al. did using T2* and proton density-weighted images to differentiate iron-
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labeled cardiomyocytes from the infracted myocardium, which also appeared as signal
loss.36
Most reports in the current literature suggest that while rats and other mammals develop
fluid-filled cysts after SCI, mice do not.8, 64, 65 Micro-cysts have been reported in mice,
but not central cavities,6,

66

and moderate cavities have been reported in mice using a

displacement contusion model.66 In our experiments, MRI revealed the presence of large
cystic lesions rostral to the epicenter of the SCI, at a distance much farther than is
typically interrogated by histology. The 3D image data allowed the volume of these cysts
to be calculated. The cyst volume increased with time for each of the 3 animals in which
this pathology was observed. The cysts that we observed resemble what has been
described in the literature as post-traumatic syringomyelia,67 a relatively rare
complication secondary to SCI68 which is not fully understood.
In this paper we also presented initial results of in vivo stem cell tracking in mouse SCI,
the first of its kind. In the past few years MSC have been explored as an option to
promote functional recovery after SCI in the rat69, 70 and the mouse71 and their role in
neurogenesis and functional recovery in a non-human primate SCI model was studied
with encouraging results.72 While there are still many questions remaining on the topic of
stem cell engraftment, MSC represent a promising option for cell therapy following SCI
and cellular MRI may play an important role in answering these questions.
We applied our microimaging technology to monitor the fate of iron-labeled MSC after
their implantation directly into the injured mouse cord. The presence of the cells in the
cord was easy to recognize as a large localized region of signal loss and could be
monitored over time in vivo. The volume of the signal void could be measured and was
found to diminish in size with time. This cellular imaging technology will allow us to
study factors that influence stem cell survival and engraftment by providing 3D in vivo
image data at multiple time points, post cell transplantation under various conditions.
Future work in our lab will expand on this pilot study of MSC tracking with a focus on
validating the ability of MRI to accurately detect and monitor iron labeled cells and on
comparing MRI results with locomotor outcomes.
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An additional concern, and potential limitation of tracking iron labeled cells with MRI, is
that free iron, that might be released from dead or dying MSC, may be mistakenly
reported as viable cells. Or, that iron released from dead cells might be taken up by
macrophages and similarly be incorrectly identified as viable MSC. Previous cell tracking
studies have shown that with the rejection of cells, as an example, after transplantation
into the liver, regions of signal loss disappear within days, as they are cleared by resident
Kupffer cells.73 A recent paper by Pawelczyk et al., which studied iron uptake by
bystander cells in an in vitro model system, indicates that the transfer of iron particles to
macrophages, from dead, iron- labeled cells, accounts for <10% of the total iron in the
labeled cells.74 These data advocate caution, since the implantation of iron-labeled cells
into tissues can result in uptake of label by macrophages, but also, suggest that the
amount of iron in these cells may quite low and that iron particles will be degraded
relatively quickly.
In conclusion, these results demonstrate the potential of in vivo MRI for detecting and
monitoring the pathology associated with spinal cord injuries in mice and for tracking the
fate of transplanted stem cells. The ability to follow SCI noninvasively in mice will
permit the evaluation of various treatments. MR tracking of transplanted cells may
become a powerful tool for understanding the mechanisms that are responsible for the
successful migration, survival and expansion of transplanted cells in vivo.
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Chapter 3

3

The Use Of Cellular Magnetic Resonance Imaging To
Track The Fate Of Iron-Labeled Multipotent Stromal Cells
After Direct Transplantation In A Mouse Model Of Spinal
Cord Injury†
Labeling cells with iron particles allows for their detection by magnetic resonance
imaging (MRI). This imaging approach has been used to detect and track a variety of cell
types in a number of different animal models of disease.1-8 Areas containing iron-labeled
cells appear as regions of low signal intensity on MRI images, creating negative
contrast.9 Research aimed at visualizing transplanted cells in experimental diseases of the
central nervous system (CNS) has provided good examples for the use of these tools.10-16
So far, nearly all studies have been of the ‘proof-of-principle’ type, demonstrating that
various types of superparamagnetic iron particles and labeling strategies are useful for the
long-term non-invasive MR tracking of transplanted cells.
Spinal cord injury (SCI) is an example of a difficult neurological problem with limited
therapeutic options, where stem cells have renewed hope that repair and recovery from
CNS trauma is possible.17-21 Recent reports show that several types of stem cells can be
induced to differentiate into neural cells.22, 23 A variety of cell types have been used as
transplants in SCI, including cells normally associated with inflammatory reactions, that
is: macrophages,24, 25 T-cells,26 and dendritic cells;27 and cells with stem cell properties:
namely embryonic stem cells,28 neural stem cells (NSC),29 bone marrow derived
multipotent mesenchymal stromal cells (MSC)30-33 and, hematopoietic stem cells.18

†
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Science+Business Media: Molecular Imaging and Biology, The Use of Cellular Magnetic Resonance
Imaging to Track the Fate of Iron-Labeled Multipotent Stromal Cells after Direct Transplantation in a
Mouse Model of Spinal Cord Injury, Vol. 13, 2011, p. 702-711, Laura E. Gonzalez-Lara, Xiaoyun Xu,
Klara Hofstetrova, Anna Pniak, Yuhua Chen, Catherine D. McFadden, Francisco M. MartinezSantiesteban, Brian K. Rutt, Arthur Brown, Paula J. Foster, Figures 3.1-3, 3.5, 3.9-10, 3.12 ©Academy of
Molecular Imaging and Society for Molecular Imaging, 2010

69

Remarkably, all of these paradigms improve recovery after SCI, suggesting that some of
the effects are independent of the source of donor cells.
Stem cells have been administered to SCI patients.34-38 Moviglia et al. have performed a
preliminary study of the intra-arterial transplantation of autologous NSC in two patients
without adverse effects.36 Two other groups have evaluated the effect of autologous bone
marrow derived stem cells transplanted into both the injury and intravenously (i.v.).34, 35
Still, many important questions persist relating to the best protocols for delivering
adequate numbers of stem cells. For example, there is no official consensus on the best
route of administration or the optimal number of stem cells to be administered. Central to
the future success of cell transplantation is the ability to noninvasively assess the fate,
migration patterns and survival of transplanted cells. The use of MRI for tracking stem
cells after their administration can provide a more dynamic view of cellular events in
vivo and should provide insights into many basic and practical questions regarding cell
therapies that can be directly translated into human clinical applications.
A potential limitation of tracking iron labeled cells with MRI is the possibility of transfer
of the label to local bystander cells (i.e. macrophages) potentially confusing the
interpretation of viable transplanted cells in the images. Terrovitis et al. reported that
signal loss in MR images persisted for three weeks after cardiac transplant, while
histology at three weeks showed only iron labeled macrophages at the transplant site, and
few or no viable stem cells.39 Additional studies are required to know whether the
transfer of iron labels is particular to certain transplant protocol, or to specific types of
injury or disorder, and whether long-term cell tracking by MRI using magnetic particles
is out of the question, or only something we need to be sensitive to when interpreting our
data. Here we report on a study where MSC labeled with micron sized iron oxide
particles (MPIO) were administered by direct transplant in a mouse model of SCI and
monitored in vivo for 6 weeks by MRI.
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3.1 Materials and Methods
3.1.1

Animal Model

All protocols for these experiments were approved by the University of Western Ontario
Animal Care Committee in accordance with the policies established by the Canadian
Council on Animal Care.
A clip compression SCI was induced in C57/Bl6 (n=17) and K15-EGFP (n=16) 20-25g
female mice at the 4th thoracic (T4) level, as it has been previously described.40 Mice
were premedicated with atropine sulfate (0.05 mg/kg s.c.; MTC Pharmaceuticals,
Cambridge, ON, Canada) and placed on a heating pad to maintain body temperature.
Surgical anesthesia was achieved using isoflurane USP (1.5% to induce and 1.25% to
maintain; A bbott Laboratories, Saint-Laurent, QC, Canada) in oxygen at a rate of 1 l/min,
delivered through a nose cone. With the assistance of a surgical microscope, a
laminectomy was performed to expose the T4 segment of the spinal cord, as described by
Joshi and Fehlings,41 and a FEJOTATM clip was used to compress the cord extradurally
for 60 seconds, with a force of 8g. The muscles and the skin were closed with 4-0 Vicryl
and the animals were allowed to recover under a heating lamp and then on a heated water
pad. All animals were treated with buprenorphine (0.1 mg/kg s.c.; Temgesic, ScheringPlough, Hertfordshire, UK) as needed and 5 mg/kg of Baytril (Bayer, Toronto, ON,
Canada) and 0.5ml (1ml on the day of surgery) of 0.9% saline twice daily for three days.
Bladders were voided twice daily by manual compression.

3.1.2

Transplantation Model

Bone marrow derived MSC were transplanted into SCI mice. The donor strain
(Tg(ACTBEGFP)1Osb), expresses enhanced green fluorescent protein (EGFP) under the
control of the chicken beta-actin promoter and cytomegalovirus enhancer in all tissues,
with the exception of erythrocytes and hair.42 One of the recipient strains, K15-EGFP,
expresses EGFP under the direction of the mouse keratin complex 1, acidic, gene 15
promoter. This promoter limits EGFP expression to the hair follicles in the skin.43 These
mice are the ideal donor-recipient pair as these transgenics were generated on the same
genetic background, C57Bl6, which we used as our other recipient strain. Hence the
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transplants should be fully compatible with the hosts and easily detected by their
expression of EGFP.
Whole bone marrow was acquired from the femurs of 3-6 month old male mice and
plated onto T-25cm2 tissue culture flasks (BD Falcon™, Mississauga, ON, Canada) by
adherence. The flask contained 5ml of Dulbecco/Vogt modified Eagle's minimal essential
medium (DMEM) with 10% fetal bovine serum, 2mM L-glutamine, 100 units/ml
penicillin and 100 µg/ml streptomycin and cells were kept at 37ºC in 5% carbon dioxide.
Twenty-four hours after cultured, non-adherent cells were removed and once adherent
cells reached 80% confluence they were passaged with fresh medium (1:3 dilution) every
2-3 days. MSC were characterized by flow cytometry using antibodies raised against a
battery of markers at passage four, including c-kit, CD11b, CD31, CD34, CD45 and
relative isotype controls.
To label cells with MPIO for MRI detection, they were plated at a concentration of 8x104
c/ml in DMEM. The cells were labeled using 10µl of magnetic silica particles (SiMAG,
0.75µm; chemicell, Berlin, Germany) and incubated for 24hrs at 37ºC in 5% CO2. Cells
were then washed with Hank's balanced salt solution (HBSS; GIBCO®, Invitrogen™,
Burlington, ON, Canada) three times and trypsinized using 0.25% Trypsin-EDTA
solution. Three additional washes with HBSS were performed before counting the cells.
Trypan blue exclusion and flow cytometric assays were performed to examine potential
effects of iron oxide particles on cell viability and functionality. The trypan blue
exclusion assay was performed after labeling the cells both before and after passing the
cells through the needle, to assess the effect of the injection process on the cells. For flow
cytometry, after harvesting, cells were resuspended in 1xBinding Buffer to a
concentration of 106 c/ml and 100µl aliquots were prepared for each sample. Tubes
contained either 5µl of Annexin V-APC (Allophycocyanin), 7-AAD-PE (7Aminoactinomycin D conjugated with Phycoerythrin), or both. These samples were
incubated for 15min at room temperature in the dark and then run through a 50µm filter
with 400µl of 1xBinding Buffer into a new tube. Cytospin slides with 2x105 labeled or
unlabeled cells were stained with Perls’ Prussian Blue (PPB) to confirm the presence of
iron and eosin to stain for cytoplasm.
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Labeled and unlabeled cells were harvested and placed in 5ml of fixative solution, 2.5%
gluteraldehyde in 0.1M sodium cacodylate buffer. The sample was spun down and
resuspended in 1ml of 0.1M cacodylate buffer before being washed, enrobed in 5% noble
agar, washed again and fixed in 2% uranyl acetate. Afterward it was dehydrated with
ethanol. The sample was then infiltrated with varying concentrations of epon resin to
propylene oxide and embedded in polymerize resin. Finally, the sample was cut into thin
(60-90nm) sections and placed on formvar/carbon film 300 mesh grids to view with
transmission electron microscopy (TEM).
The dura was excised at the epicenter of the SCI (T4 level) for an intra-spinal transplant.
Using a spinal stereotaxic frame, 3x104 cells in 3µl of saline were transplanted with a
glass pipette (tip diameter=100µm) configured to a 10µl Hamilton syringe.44 Five groups
of SCI mice were used. Group 1 (n=18) received 3 x 104 MPIO-labeled MSC within one
week after SCI. Group 2 (n=4) received 3 x 104 MPIO-labeled MSC that had been treated
with sodium nitroprusside (1mM) prior to transplantation to induce apoptosis, Group 3
(n=4) received MPIO particles equivalent to the iron content in 3 x 104 cells (0.83 mg/ml)
diluted in saline, Group 4 (n=3) received 3 x 104 unlabeled MSC, and Group 5 (n=4) did
not have a transplant.

3.1.3

Magnetic Resonance Imaging

Mice were imaged using a 3 Tesla (3T) GE whole-body MR scanner (MR Signa®
Excite™, GE Healthcare, Milwaukee, W I, USA ) using a custom-built gradient coil (inner
diameter=17.5cm, maximum gradient strength=500 mT/m, and peak slew rate=3000
T/m/sec). Mice were anesthetized with isoflurane (2%) and placed on a custom-built
plastic sled to permit careful and reproducible positioning to allow sagittal imaging of the
cord. The sled was positioned within a custom-built solenoid radiofrequency (RF) coil,
which is 4cm in length and 3cm in diameter, allowing for the acquisition of whole mouse
body images. The lower part of the body and tail were wrapped using gauze to maintain
body temperature.45 Mice were scanned using a 3D balanced steady state free precession
(bSSFP) pulse sequence (3D-FIESTA; GE Medical Systems, Milwaukee, W I, USA ;
TR/TE=3.8/1.8ms, flip angle=25º, 4cm x 2.4cm FOV, 128 locs per slab) at 200µm
isotropic resolution with 16 NEX and 2 RF phase cycles. Acquisition time was 31 min.
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Mice recovered under a heating lamp. SCI mice were imaged on day 0, day 2 and 1, 2,
3/4 and 6 weeks post transplantation.

3.1.4

Image Analysis

Images of injured cords were assessed for changes in signal intensity at the lesion
epicenter. 3D image data allowed for an analysis of patterns of image contrast in all
orientations. Images of transplanted mice were assessed for regions of signal loss due to
the presence of MPIO-labeled cells. The volume of these regions was measured by
manual segmentation using the open-source imaging software OsiriX.46 The volume for
the region of signal loss for each animal was normalized to day 2. Volumes were
measured for each time point, averaged for each group separately and the standard error
of the mean (SEM) was calculated for each group. Two independent observers measured
the volumes of the regions of signal loss for all animals for each time-point, for at least 4
weeks. Inter-observer variability in volume measurement was assessed using analysis of
variance (ANOVA).

3.1.5

Histology

After the final imaging session the mice were induced with deep anesthesia and
transcardially perfused. The spinal cords were removed and placed in phosphate buffer
up a sucrose gradient (10%, 20%, 30%) at 4°C. Cord tissue was sagittally sectioned on a
cryostat set at 16µm. The sections, which were 6-8mm in length with the lesion epicenter
in the middle of the section, were serially collected on gelatine-coated glass slides,
alternating between two slides resulting in adjacent sections with different stains. For
each animal approximately one third of the slides was stained with PPB, for visualization
of the iron particles, and nuclear fast red for visualization of the cord and lesion
morphology. A second portion of the slides was stained with anti-GFP, IgG, Alexa
Fluor® 488 conjugate (Invitrogen; Eugene, OR, USA ) to highlight the EGFP+ MSC.
Finally, the third portion of the slides was stained with Biotin Anti-Mouse Macrophage
(F4/80) Monoclonal Antibody

(CEDA RLA NE Laboratories Ltd.; Burlington, ON,

Canada) and TSA™ (Tyramide signal amplification) Biotin (PerkinElmer; W oodbridge
ON, Canada) to identify macrophages. VECTASHIELD® HardSet™ Mounting Medium
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with DAPI (V ector Laboratories Inc.; Burlingame, CA , USA ) was used to identify the
nuclei using fluorescence. Stained sections were visualized using optical or fluorescence
microscopy with a Zeiss AXIO Imager (Carl Zeiss Canada Ltd.; Toronto, ON, Canada).

3.2 Results
3.2.1

Cell Labeling

In TEM images the iron core of the MPIO particles could be detected within endosomes
in the cell cytoplasm of the labeled MSC (Fig. 3.1 a&b). PPB staining also showed that
the iron particles were located within the cells (Fig. 3.1c). Labeling MSC with MPIO did
not affect cell viability; the trypan blue exclusion assay showed that 94% of labeled and
98% of unlabeled cells were viable after harvesting (Fig. 3.1d) (from an average of 4
samples for each) and that 89% of the labeled cells were viable after passing through the
needle used for transplantation.
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Figure 3.1: Mouse MSC labeled with MPIO. In electron microscope images, the iron
cores of the MPIO particles appear as dark clusters contained within endosomes (a and b,
arrows). PPB staining shows the iron particles (blue) within the cells (c). A trypan blue
exclusion assay showed that labeling MSC with MPIO did not affect cell viability; 94%
of labeled and 98% of unlabeled cells were viable after harvesting (d).
Representative Annexin V/7-AAD flow cytometry dot plots for unlabeled (control) and
MPIO-labeled MSC are shown in Figure 3.2. There was no statistically significant
difference in the numbers of unlabeled or MPIO labeled cells that were nonviable (7AAD) or apoptotic (Annexin V).
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Figure 3.2: Flow cytometric analysis of viability in MPIO-labeled and unlabeled MSC.
Top panel shows results of Annexin V binding. The Annexin-V-positive population
contains early apoptotic cells. The bar graph shows the mean percentages of Annexin-Vpositive cells+standard deviation. There was no significant difference in the percentages
of Annexin-V-positive cells for unlabeled (10%) or MPIO-labeled (13%) MSC (n=3
each). Representative dot plots for Annexin V are also shown for one sample where (a)
and (b) indicate the percentages of live and apoptotic cells, respectively. Bottom panel
shows results of 7-AAD permeability. The 7-AAD positive population contains
nonviable cells. The bar graph shows the mean percentages of 7-AAD positive cells+SD.
There was no significant difference in the percentages of 7-AAD positive cells for
unlabeled (10%) or MPIO labeled (16%) MSC (n=3 each). Representative dot plots for 7AAD are also shown for one sample where (a) and (b) indicate the percentages of live
and nonviable cells, respectively.

3.2.2

Magnetic Resonance Imaging

3D whole mouse body anatomical images were acquired in the sagittal orientation at 3T
using a bSSFP pulse sequence in a relatively short time (31min) for high resolution MRI
at clinical fields. Maintaining a short scan time was important as the secondary effects of
SCI include diminished thermal regulation, decreased breathing capacity, and deficits in

77

cardiovascular function,47 making the mice more susceptible to complications due to
anaesthesia and the inherent cold temperature of MRI systems, even when using
compensating mechanisms. This was a significant consideration as in this longitudinal
study the mice were scanned up to three times in one week. Figure 3.3 shows a
representative image of a SCI mouse, which received no cell transplant, two weeks after
the injury. The spinal cord has a significant curvature and the entire length of the cord is
visible. The epicenter of the SCI is visible as a small, subtle region of altered signal. In
SCI mice the contrast at the epicenter of the SCI changes slightly over time becoming
more hypo-intense.

Figure 3.3: Representative sagittal image of a mouse from Group 5, which received no
transplant. Two weeks after SCI the lesion site (arrow) is observed as a small, subtle
region of altered signal. Other organs are labeled for anatomical reference.
Representative images from a mouse that received a direct transplant of MPIO-labeled
MSC, show clear areas of signal loss within the cord (Fig. 3.4). This is an example of
what we refer to as a ‘successful’ intra-spinal transplant since the images show regions
of signal loss within the spinal cord on the day of the transplant, and not outside of the
cord or in surrounding tissues. As the MRI data was acquired in 3D, this allowed for
manual segmentation in any plane, such as an oblique axial to adjust for the natural
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curvature of the mouse cord. The bottom panel in Figure 3.4 shows axial images through
the cord at different levels. This view helps to verify that the areas of signal loss are in
fact within the cord, close to the central canal (1: blue arrow, Fig. 3.4.b), by the dorsal
column (2: red arrow, Fig. 3.4.c) and closer to the cerebrospinal fluid (CSF) (3: yellow
arrow, Fig. 3.4.d).

Figure 3.4: Representative sagittal image (a top) of a mouse that received a successful
transplant of MPIO-labeled MSC and corresponding cord areas in an axial plane
(bottom). Clear areas of signal loss were observed within the cord: close to the central
canal (b, 1: blue arrow), by the white dorsal column (c, 2: red arrow) and closer to the
CSF (d, 3: yellow arrow). D-dorsal, V -ventral, R-rostral, C-caudal.
Representative images from SCI mice that received MSC or free MPIO particles
transplants are shown in Figure 3.5.

In the images of all SCI mice that received

successfully MPIO-labeled MSC a large, well-defined region of signal loss was observed
within the cord at the site of the cell transplant (Fig. 3.5a). The MR appearance of the
transplant site in the cords of mice that received dead, MPIO-labeled MSC (Fig. 3.5b) or
MPIO particles (Fig. 3.5c) though was similar to that of live MSC.
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Figure 3.5: Iron-labeled MSC appeared as well-defined regions of signal loss in the
mouse spinal cord at the site of transplant. Sagittal views of the cord where regions of
signal loss can be seen at the site of transplantation. The epicenter is indicated by the
arrowheads. SCI mice that received: (a) live MPIO-labeled MSC, (b) dead MPIO-labeled
MSC, and (c) MPIO only, at different points post transplantation. The MR appearance of
dead, iron-labeled MSC was similar to that of live MSC. While the volume of the region
of signal loss decreased over time for all groups, it was still present in all at the end of the
study at 6 weeks after transplantation. D-dorsal, V -ventral, R-rostral, C-caudal.
There was no significant inter-observer variability (p>0.48) in the measurements of
regions of signal loss. At day 2 post transplant the average volume of the region of signal
loss within the cords was 2.5mm3 for live MSC, 1.0mm3 for dead MSC, and 3.5mm3 for
free MPIO particles. In all transplanted SCI mice the region of signal loss appeared to
shrink over time. However, a substantial amount of signal loss persisted at the transplant
site, in all mice, at the end of the experiment. The rate at which the region of signal loss
decreased with time varied, although not significantly, for the three groups of mice. The
size of the void diminished most quickly in mice that received live MSC and most slowly
in mice that received MPIO. At six weeks after transplantation the signal void volume in
mice that received live MSC had decreased to 34±6.6% of the initial volume (an average
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from n=8, expressed as the mean±SEM). In mice that received dead MSC the void
volume had decreased to 49±7.5% (from n=4) of the initial volume at six weeks. For the
group of mice that received MPIO particles the void volume only decreased to 68±22.3%
(from n=4) the initial value at six weeks.
Surprisingly, in 4 cases it seemed a successful intra-spinal transplant was not achieved.
Figure 3.6a shows that, in these mice, no signal loss was observed within the spinal cord
at the level of the epicenter (arrowhead), the intended site of transplantation. Inspection
of the 3D image data revealed that signal loss was in the surrounding tissues (arrows). A
closer look to a different but nearby MRI slice also shows these areas of signal loss above
the cord (arrows, Fig. 3.6b). An axial view clearly shows a large area of signal loss above
the cord with a track that can be followed to the surface (arrows, Fig. 3.6c).
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Figure 3.6: Representative sagittal image (a) of a mouse where the intended intraspinal transplant of MPIO-labeled MSC was not achieved. Areas of signal loss are not
present within the cord, but can be found in the surrounding tissue. (b) A different slice
also shows areas of signal loss dorsally of the cord that leave a track to the surface. (c)
An axial view confirms an area of signal loss on the dorsal left side of the cord, but not
within the cord. Other organs are labeled for anatomical reference. D-dorsal, V -ventral,
R-rostral, C-caudal.
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In 7 cases, where the transplant was deemed successful, additional regions of signal loss
were observed in unexpected locations, mainly along the dorsal edge of the cord in the
cervical spinal cord, possibly within the CSF. In Figure 3.7 representative images show
signal loss in the cervical cord that persisted for 6 weeks, gradually diminishing in size.
In some cases regions of signal loss were observed in the brain.

Figure 3.7: Areas of signal loss far from the site of transplantation (arrowhead) in a
mouse that received a direct transplant of MPIO-labeled MSC. The signal loss appears to
be in the dorsal portion of the first few cervical vertebral segments, aligned and within or
adjacent to the CSF. The overall pattern of this secondary area of signal loss changed
slightly week to week, and although smaller in volume it was still present at the end of
the study.
In Figure 3.8 signal voids appear in close proximity to the third ventricle in images
acquired on the same day as the transplant (Fig. 3.8 a&c). The size of these areas of
signal loss decreased and had subtle changes in the pattern over time but persisted in the
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same location until the end of the study (Fig. 3.8 b&d). The observation of signal void far
from the lesion epicenter was not noted in animals that received dead cells or free iron.

Figure 3.8: Sagittal (a&b) and axial (c&d) images of a mouse that received a direct
transplant of MPIO-labeled MSC. Areas of signal loss were observed on the day of the
transplant (a&c) within the brain. Although these areas of signal hypo-intensity
decreased in size, they were still present at the end of the study at 6 weeks (b) notably
within the third ventricle (d). Scale bar on b applies to a&b, and on d applies to c&d. Ddorsal, V -ventral, R-rostral, C-caudal.

3.2.3

Histology

MR images of the cord were compared with PPB stained cord sections six weeks after the
transplant. In Figure 3.9, representative MRI and PPB staining is compared showing
good correspondence between the regions of signal loss and blue staining due to iron for
the animals that received live MPIO-labeled MSC (top row), dead MPIO-labeled MSC
(middle row), and free MPIO (bottom row). Two different types of PPB staining were
observed at the injection site, concurrently, and in all groups. In some areas the PPB
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staining appeared extracellular (arrowheads, Fig. 3.9c) and frequently formed dense
clusters (Fig. 3.9i). In other areas the PPB staining appeared intracellular (arrows Fig.
3.9c) and lighter (Fig. 3.9f).

Figure 3.9: At 6 weeks after the transplant the pattern of signal loss in the MRI images
of the cord for the animals that received (a) live MPIO-labeled MSC, (d) dead MPIOlabeled MSC, and (g) free MPIO matched the PPB staining of the cord (b, e, and h). The
iron was observed in two different patterns, one appeared to be extracellular (c,
arrowheads) and more concentrated (i), while the other appeared intracellular (c, arrows)
and usually fainter (f). These two patterns were observed in all groups.
Figure 3.10 shows an overlay of micrographs of an unstained cord section and after DAPI
staining of nuclei in the same section. The DAPI fluorescence image was converted to
black and white to produce maximum contrast between the black nuclei and the rust
colored iron. This microscopy image clearly shows the difference between clusters of
MPIO particles outside of cells (arrows) and heavily loaded cells (arrowheads).
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Figure 3.10: An overlay micrograph is shown of unstained cord tissue where MPIO
particles appear rust colored and DAPI staining of nuclei in the same section. The DAPI
fluorescence image was converted to black and white to produce maximum contrast.
A rrows indicate clusters of MPIO particles outside of cells and arrowheads point to
heavily loaded cells where the nucleus is easily observed.
Figure 3.11 compares fluorescence images of EGFP with PPB staining near the lesion
epicenter for a SCI mouse that received live MPIO-labeled MSC. There is good
agreement between areas containing cells that are EGFP+ and cells that are PPB+.
Tissue that does not appear to contain any PPB+ cells is not visible in the fluorescence
image. Again, some of the areas with blue PPB staining appear denser than others,
although most of the PPB+ staining appears to be intracellular. While this is an example
where there is good correspondence between PPB+ and EGFP+, not all PPB+ sections
were matched to EGFP+ sections.
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Figure 3.11: In animals that received live iron-labeled MSC, immunostaining showed
GFP+ areas (a) that could be matched to PPB+ cells (b). Both images taken with a 20x
objective.
F4/80 staining revealed macrophages mostly present at the epicenter of the injury (Fig.
3.12). There were few macrophages detected in the sections from the animals that
received live, MPIO-labeled MSC (Fig. 3.12a). Sections from SCI mice that received
dead, MPIO-labeled MSC or free MPIO particles contained many more macrophages
(Fig. 3.12 b&c). Cells that were both PPB and F4/80 positive were observed only
occasionally in all mice. For the most part iron positive cells in the cord did not colocalize with macrophage staining.
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Figure 3.12: At 6 weeks after transplant, macrophage staining (F4/80) revealed few
macrophages present at the epicenter of the injury for animals with live, MPIO-labeled
MSC (a), and more macrophages in animals that received dead, MPIO-labeled MSC (b)
and MPIO only (c).
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3.3 Discussion
Now that cell transplant therapies are being explored for many disorders, interest in the
use of cellular MRI to track cells in animal models of disease is growing rapidly. There
are numerous studies that demonstrate that MRI of iron-labeled cells allows for their
detection after transplantation.2, 48-53 However, cell death and subsequent phagocytosis of
iron particles by macrophages may render the MRI signal nonspecific for tracking cells
for long periods of time after transplantation. The results of this paper showed that iron
oxide labeling and MRI may be useful for the in vivo visualization of the cell transplant
in the spinal cord but these methods are not reliable for tracking the fate of transplanted
cells in all tissues and models.
The main finding of this study is that signal hypo-intensities observed by MRI after the
transplantation of iron-labeled cells may not reliably represent the original donor cells.
This was determined by performing a longitudinal imaging study that followed SCI mice
for six weeks after the direct transplantation of viable iron-labeled MSC, dead ironlabeled MSC or free iron particles, and where the MRI appearance of the region of signal
loss at the transplant site was found to be remarkably similar for all three groups.
In all transplanted SCI mice the volume of signal loss decreased over time. However, a
substantial amount of signal loss persisted at the transplant site, in all mice, at the end of
the experiment. The reduction in volume of signal loss was not surprising since many
stem cells are expected to die from the transplant itself54 and in the hostile environment
of SCI.55 The direct transplantation of stem cells into target tissues is known to result in a
large percentage of the donor cells dying. Coyne et al. transplanted GFP+ MSC into the
rat striatum and found that the surgery itself elicited an immediate inflammatory
response, MSC grafts were massively infiltrated by microglia/macrophages and by 14
days, the GFP immunoreactivity was absent, indicating complete donor rejection.56 In a
similar model Moloney et al. also reported a considerable reduction in the size of the
graft volume by day 7, albeit MSC were still detectable by day 42 after transplantation.57
Both reports are in agreement with a study by Xu et al. that reported that there is a
significant decrease of directly transplanted MSC within the first few weeks in a SCI
mouse model with only ~3% cells surviving past 3 weeks and less than 1% by 6 weeks.55
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The decline in the size of the original signal void volume was greatest in SCI mice that
received live MPIO-labeled cells. There were also very few macrophages in the spinal
cord sections from mice transplanted with viable MSC. This is expected since
macrophage infiltration due to SCI peaks at 5-7 days and then slowly decreases over the
next 2-5 weeks.58 In addition, the administration of MSC in mouse SCI has been shown
to have a beneficial effect attributed to a reduction in the number of monocyte-derived
macrophages at the injury site.55 Although the cell number is expected to decline with
cell death and the signal void volume decreased with time, the void volume is probably
an overestimation of the live MPIO-labeled MSC since some bystander cell uptake of
iron is likely. 39
The fact that the size of the void diminished more slowly in the mice that received dead
MPIO-labeled cells, and even more so in mice that received free MPIO, was interesting.
PPB staining showed areas of dense extracellular iron present in the injured cord tissue at
6 weeks post transplant. The free iron particles purposefully transplanted into the injured
cord were also found lodged in the damaged cord tissue at 6 weeks post injection. These
observations are consistent with those of Berman et al. where iron from cells transplanted
directly into the mouse brain was retained in the extracellular space in brain tissue for
long periods of time making it difficult to distinguish between viable and dying cells.59, 60
There were many more macrophages present in the cords from mice injected with dead
MSC or free MPIO particles, compared to the cords of mice that received live MSC. The
presence of free MPIO particles and dead MSC may trigger an additional inflammatory
response increasing the number of macrophages present at the site of transplant.
Macrophages may engulf dead cells and their debris, becoming iron-labeled
secondarily.61 In addition, the possibility exists for the transplanted cell population to
contain cells with iron particles attached to their surface, or to contain free iron particles
in the solution, and in both of these situations there is the potential for the iron particles to
be released into the target tissue and taken up by bystander cells. Therefore, although
MRI of iron-labeled cells is very useful for locating transplanted cells and for evaluating
the delivery of transplanted cells to the target tissue in the early phase, the potential for
transfer of the iron label to other cell types in the longer-term is a significant limitation.
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Our results are consistent with a study by Jackson et al. where live and dead iron-labeled
MSC were transplanted directly into the injured striatum in a rat model of Parkinson’s
disease. The region of signal void due to live iron-labeled MSC was tracked in vivo for
28 days. The signal loss due to dead iron-labeled MSC appeared similar but became
fainter after 21 days.62 Pawelszyk et al. have quantified the frequency of the transfer of
intracellular labels to host macrophages that phagocytosed the label or labeled cells.63, 64
They concluded that only 5-15% of the iron label was taken up by the host macrophages.
Dunning et al. transplanted MPIO-labeled Schwann cells (SC) directly into toxin-induced
demyelinating lesions in the rat spinal cord and imaged the rat spinal cord in vivo at 5
days post transplant and ex vivo at 4 weeks post transplant. To establish the contribution
of labeled SC to the observed signal void, the number of SC containing MPIO were
counted. They calculated that >50% of the SC in the lesion retained at least one
microsphere. MPIO particles were also observed within macrophages. The ratio of
labeled MPIO+ SC to MPIO+ macrophages was 2:1.65 The observation of transfer of the
iron label from donor cells to macrophages has also recently been reported in three papers
where stem cells were transplanted directly into the rat heart.39, 66, 67
Ours is the first study to use in vivo MRI to monitor the fate of stem cells after their
direct transplantation into the injured spinal cord in mice. Sykova et al. showed that ironlabeled MSC administered i.v. in SCI rats can be detected as regions of signal loss in ex
vivo images of the cord at 4 weeks after the cell injection.16, 68 They also showed that
iron positive cells in the cord did not co-localize with macrophage staining, suggesting
that iron labeled MSC persist and can be tracked with MRI. Our findings, after direct
transplantation of MSC in SCI mice, are comparable.
The homing of iron-labeled stem cells, after their systemic administration, has also been
evaluated by MRI.5, 69, 70 Song et al. used MRI to detect iron-labeled human NSC that had
been administered i.v. in a rat model of focal cerebral ischemia.5 The maximal signal
hypo-intensity was observed at 28 days after i.v. injection. Histology showed PPB+
cells, which were identified as grafted human NSC, and not phagocytic macrophages,
because they did not express the activated microglial/macrophage markers OX6 and
BrdU. MRI has also been used to track a variety of other cell types in disease models. For
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example, iron-labeled pancreatic islets have been transplanted into the mouse liver by
intraportal infusion in a model of diabetes with the goal of restoring insulin. Regions of
signal loss were detected in the liver immediately after the islet transplantation. The
regions of signal loss due to isografts persisted in the liver much longer than the signal
loss due to allografts and xenografts, which disappeared from the images with time as the
islets were rejected.71 The adoptive transfer of iron-labeled DC in mice has been
successfully monitored using MRI. Here the subcutaneous injection of DC into the
footpad resulted in the migration of DC to the draining popliteal lymph node, which was
detected as signal loss in the node two days after the injection. This signal loss was no
longer apparent at 7 days post injection, nor were DC detected by histology, indicating
that the DC, which have a lifetime of 4-7 days, had been cleared.72 Collectively, the
results of many recent studies indicate that the MRI appearance of transplanted cells must
be interpreted with caution and that the identity of donor cells must be carefully validated
by histology.
It was interesting to find areas of hypo-intensity in the brain and dorsal cervical areas of
the cord in animals that received live MPIO-labeled MSC. These signal voids appeared to
be in close proximity to, or within, the CSF.

The enlargement of CSF containing

structures after traumatic SCI has been reported in rabbits and rodents.73, 74 Changes in
CSF flow direction and pressure have been proposed as mechanisms that promote the
development of cysts.75 The presence of cysts in the mouse cord (as shown in Chapter 2)
may lead to abnormal CSF flow which might explain the movement of iron-labeled cells
rostral to the injection site as early as the day of transplant, and this could explain these
areas of signal loss. These areas of signal loss were not observed in animals that received
dead cells or free MPIO.
While MRI long-term cell tracking needs to be approached with caution and thoroughly
validated through histology, MRI does allow us to verify the delivery of the cells to the
intended target in vivo. In experimental studies of stem cell transplantation this is
important because the stem cell survival and homing is typically assessed by histological
analysis at endpoint.17, 55 MRI can provide knowledge that the cells were delivered to the
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intended target in the first place so that only those successful transplants are included in
the final histological evaluation.
Since there is currently no consensus regarding the best route of delivery of cells for stem
cell therapy MRI may be useful for evaluating the likelihood of successful cell delivery
with the various methods being considered for SCI in the clinic including intra-arterial36
and intravenous34, 37 infusions, lumbar puncture,76 and direct transplantation.35 De Vries
et al.,77 labeled dendritic cells (DC) with SPIO to evaluate the success of injections
directly into the lymph nodes of melanoma patients. While the injections were performed
under ultrasound guidance by an experienced radiologist, they reported that ~50% were
failed injections. They also described, that cell migration to nearby nodes was only
observed in the patients that had a successful injection and that this should be considered
as a potential explanation for the lack of response to DC vaccinations in a number of
patients in ongoing clinical trials.

3.4 Conclusion
MRI of iron-labeled cells is very useful for locating transplanted cells and for evaluating
the delivery of transplanted cells to the target tissue in the early phase; however, signal
hypo-intensities observed by MRI after the transplantation of iron-labeled cells may not
reliably represent the original donor cells because of the potential for transfer of the iron
label to other cell types. This was determined by performing a longitudinal imaging study
that followed SCI mice for six weeks after the direct transplantation of viable MPIOlabeled MSC, dead MPIO-labeled MSC or free MPIO particles, and where the MRI
appearance of the region of signal loss at the transplant site was found to be remarkably
similar for all three groups.
The methods of transplantation, host tissue, cell type, cell lifespan, and the extent of
inflammation in the model system, no doubt play important roles in the cell survival and
clearance. The direct transplantation models, as described here for the injured spinal
cord, and as frequently reported for the injured myocardium, may represent the worst-
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case scenario for cell tracking with MRI. In our SCI model the passage of cells through
the needle used for the transplantation did not cause a significant amount of cell death,
however the site of the injection is a hostile environment due to ongoing inflammation
and the blood flow in the injury is compromised due to the traumatic insult.
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Chapter 4

4

In Vivo Magnetic Resonance Imaging Of Acute
Inflammation After Spinal Cord Injury In The Rat: A
Preliminary Study
Impaired sensory and motor function in people who have a spinal cord injury (SCI) is the
result of not only the initial traumatic event, but also the inflammatory response to SCI,
which further damages the neural pathways, exacerbating motor and sensory deficits. The
inflammatory response involves the activation of microglia and the infiltration of
neutrophils, macrophages, and T-lymphocytes following the initial trauma to the spinal
cord.1-3 The macrophages involved in the inflammatory response to SCI have been long
considered to have a dual, ‘double-edged’ role in SCI.4 A recent report shows that this
may be in fact due to two separate subsets of macrophages present at the lesion site, with
alternatively activated macrophages (M2) having a positive role in SCI (by contributing
to the debridement and healing process) and classically activated macrophages (M1)
having a negative role in SCI (by exacerbating the injury through the release of toxic byproducts and by amplifying the inflammatory responses).5 Kigerl et al. have shown that
during the first 1-3 days after SCI the presence of M1 and M2 is equivalent, but by the
end of the first week the M2 have mostly disappeared and the M1 dominate.5 A better
understanding of the macrophage response is important for planning anti-inflammatory
treatments and cell therapy.6 Imaging macrophage infiltration in vivo may help to
elucidate their role in SCI.
MRI has been used to detect and monitor macrophages in many different preclinical
disease models. This is achieved by the intravenous (i.v.) administration of iron oxide
nanoparticles, followed by imaging, typically 24 hours later. MRI has been used to
image inflammation in experimental autoimmune encephalomyelitis (EAE)7-10, ischemic
stroke,11 atherosclerosis,12, 13 peripheral nervous system injury,14, 15 arthritis,16 SCI,17 and
rejection in a variety of transplantation models.18-23 This approach has also been used in
patients for monitoring macrophage infiltration and responses to treatment, in multiple
sclerosis (MS),24 atherosclerosis,25, 26 lymph node imaging,27 and liver imaging.28, 29
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All three of the general classes of iron oxide nanoparticles have been used for
macrophage imaging, including the ultra-small superparamagnetic iron oxide
nanoparticles (USPIO),30,
(SPIO),

10, 14, 17

31

the standard superparamagnetic iron oxide nanoparticles

and micron-size oxide iron particles (MPIO).32, 33 USPIO have been used

most frequently because their small size allows them to circulate longer, avoiding quick
uptake by the reticuloendotheial system. MPIO are only used in preclinical studies since
they are inert.
In SCI, macrophage imaging has yet to be performed in vivo. A previous study from our
lab evaluated the use of iron nanoparticles for the labeling and detection of macrophages
in the injured rat cord using ex vivo MRI at 1.5T. This study demonstrated that clusters
of iron-labeled cells associated with the inflammatory response in SCI could be detected
in bSSFP images of the rat cord.17 The purpose of this study was to implement techniques
for macrophage imaging in vivo in a rat model of traumatic SCI.

4.1 Methods
4.1.1

Animal Model

All protocols for these experiments were approved by the University of Western Ontario
Animal Care Committee in accordance with the policies established by the Canadian
Council on Animal Care.
A moderate clip compression SCI was induced in 18 female Wistar rats at the level of the
4th thoracic (T4) vertebrae as it has been previously described.34 Rats were premedicated
with atropine sulfate (0.05 mg/kg s.c.; MTC Pharmaceuticals, Cambridge, ON, Canada)
and placed on a heating pad to maintain body temperature. Surgical anesthesia was
achieved using isoflurane USP (5% to induce and 2% to maintain; A bbott Laboratories,
Saint-Laurent, QC, Canada) in oxygen at a rate of 2 l/min, delivered through a nose cone.
With the assistance of a surgical microscope, a laminectomy was performed to expose the
T4 segment of the spinal cord and a modified aneurysm clip was used to compress the
cord extradurally for 60 seconds, with a force of 35g. The muscles and the skin were
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closed with 4-0 Vicryl and the animals were allowed to recover under a heating lamp. All
animals were treated with buprenorphine (0.1 mg/kg s.c.; Temgesic, Schering-Plough,
Hertfordshire, UK) as needed and 5 mg/kg of Baytril (Bayer, Toronto, ON, Canada) and
5ml of 0.9% saline twice daily for three days. Bladders were voided twice daily by
manual compression.

4.1.2

Magnetic Resonance Imaging

Rats were imaged using a 3 Tesla (3T) whole-body MR scanner (MR Signa® Excite™,
GE Healthcare, Milwaukee, W I, USA ) using a custom-built gradient coil (inner
diameter=17.5cm, maximum gradient strength=500 mT/m, and peak slew rate=3000
T/m/sec). Rats were anesthetized with isoflurane (2%) and placed on a custom-built
Plexiglas tray to permit careful and reproducible positioning to allow sagittal imaging of
the cord. The tray was positioned within a custom-built radiofrequency (RF) transmitonly, receive-only (TORO) system (Fig. 4.1). The TORO system consisted of a 4-channel
phased array receiving RF coil (diameter=7.5cm, length=6.25cm, Fig. 4.1a), nested in a
birdcage RF coil (diameter=12cm, length=16.5cm, Fig. 4.1b) that transmits the RF
excitation pulse. Surface coils as receiving coils offer a high signal to noise ration (SNR)
but have limited surface field of view (FOV) and depth. Arranging a number of surface
coils in a phased array, 4 in this case, allows for a more homogeneous FOV over a
volume while taking advantage of the SNR of each individual surface coil. The drawback
is that surface coils fail to produce a uniform field in the transmit mode, which can be
circumvented by having a separate transmitting coil. While a solenoid coil like the one
used in Chapters 2 and 3 provides the most homogeneous excitation, the solenoid coil
must be placed perpendicular to the main field within the insert coil, which is not possible
with a rat due to size constraints. The next best option is a birdcage transmit coil that will
provide homogenous excitation with the phased array exploiting the SNR from a
receiving surface coil.
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Figure 4.1: Radiofrequency (RF) transmit-only, receive-only (TORO) system. The
receive-only RF coil is a 4-channel phased array, 6.25cm in length (blue line) and 7.5cm
in diameter (a). The transmit-only birdcage RF coil is 16.5cm in length (blue line) and
12cm in diameter (b). The tray holding the rat (blue arrow) is nested at the center of the
system, surrounded by the receiving coil, which is in turn nested in the center of the
transmitting coil (c).
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The body and tail of the rats were wrapped using surgical bench diapers to maintain body
temperature. Rats were scanned at a 200µm isotropic resolution using a 3D balanced
steady state free precession (bSSFP) pulse sequence (3D-FIESTA; GE Medical Systems,
Milwaukee, W I, USA ) with the following parameters: FOV=6cm x 3.6cm, 280 locs/slab,
BW=±27.78kHz, TE/TR= 3.8/7.6ms 4 NEX, 4 RF phase cycles, and α=40º. Following
each and every scan, rats recovered under a heating lamp.
A baseline scan was acquired 3 days after SCI and then USPIO (Molday ION™,
BioPA L, W orcester, MA , USA ) was injected i.v. and the animals were imaged again 24
hours later with the same parameters. Three doses were compared: 5mg/kg (n=3),
15mg/kg (n=7), and 30mg/kg (n=3); n=5 received no iron.

4.1.3

Image Analysis

To assess the image quality after the three different doses of USPIO the SNR was
calculated. An elliptical ROI was placed within the cord image, at least 4 vertebral
segments rostral to the epicenter, to measure the average signal intensity and this was
divided by the standard deviation of the background (‘noise’), which was measured from
a rectangular ROI selected within the same image:
𝑆𝑁𝑅 =

𝐶𝑜𝑟𝑑 (𝑚𝑒𝑎𝑛)
𝑁𝑜𝑖𝑠𝑒 (𝑆𝐷)

A SNR value was determined for each cord by averaging the calculated SNR from 10
images for each animal. SNR was compared between groups with a one-way ANOVA.
Images of injured cords were assessed for changes in signal intensity at the lesion
epicenter in images acquired before and after iron oxide administration. Two elliptical
ROIs were drawn in all cord images. One ROI was drawn in the cord at least 5 vertebral
segments rostral to the epicenter, as a measure of ‘background’ cord signal intensity. The
second ROI was drawn within regions of abnormal signal hypo-intensity at the lesion
epicenter. These ROIs were drawn in approximately the same location for images
acquired pre and post iron (equivalent slices matched by visual inspection). The contrast
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between these two regions was measured as the fractional signal loss (FSL). FSL was
calculated as:
𝐹𝑆𝐿(%) =

∆𝑆 𝑐𝑜𝑟𝑑 𝑚𝑒𝑎𝑛 − 𝑐𝑜𝑟𝑑 min
=
x100
𝑆
𝑐𝑜𝑟𝑑 𝑚𝑒𝑎𝑛

At least 5 images slices for each animal from each imaging session were used to calculate
an average FSL. Colored maps of the MR signal intensity were made for enhanced
visualization of the regions of signal loss after iron injection. This was done using a
UCLA color lookup table (CLUT). All segmentation and coloring was made using the
open-source imaging software OsiriX.35

4.1.4

Histology

After the final imaging session the rats were induced with deep anesthesia and
transcardially perfused. The spinal cords were removed and placed in phosphate buffer
up a sucrose gradient (10%, 20%, 30%) at 4°C. Cord tissue was sagittally sectioned on a
cryostat set at 20µm. The sections, which were ~15mm in length with the lesion epicenter
in the middle of the section, were serially collected on gelatin-coated glass slides,
alternating between two slides. For each animal half the slides were stained with Perls’
Prussian Blue (PPB), for visualization of the iron particles, and nuclear fast red for
visualization of the cord and lesion morphology. Stained sections were visualized using
optical microscopy with a Zeiss AXIO Imager (Carl Zeiss Canada Ltd.; Toronto, ON,
Canada).

4.2 Results
Figure 4.2 shows representative images of the injured rat cord on day 3 post SCI, before
USPIO (a), and on day 4 after SCI, 24hrs after USPIO at a dose of 30mg/kg of Molday
IONTM (b). The injured cord appears with regions of heterogeneous signal at the lesion
epicenter by day 3 post SCI. Regions of signal hyper-intensity due to edema can be seen
on both sides of the lesion epicenter (arrows) (Fig. 4.2a). Some small areas of hypo-
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intensity are also often observed at this time point. After the administration of USPIO the
contrast in the lesion epicenter is changed (Fig. 4.2b) with more obvious signal loss.

Figure 4.2: Lesion epicenter in an animal on day 3 after SCI (a) and on day 4, 24hrs
after an injection of 30mg/kg USPIO (b). W hite arrows point to the same region in both
images, which appears with more contrast (regions of low signal) after iron injection.
Figure 4.3 shows representative bSSFP images of three different rat cords after the
administration of three different doses of USPIO. The 5mg/kg dose subtly enhanced
some areas of the lesion epicenter (Fig. 4.3a), with the 15mg/kg dose there appeared to be
additional regions of signal void in the cord in all animals, compared to the smaller dose
(Fig. 4.3b), and the 30mg/kg dose produced a more obvious enhancement, but with a
substantial drop in SNR (Fig. 4.3c). The SNR of the cord, rostral to the lesion site, for
each dose is shown in Table 4.1. While the detection of signal void appeared to increase
with dose, the SNR of the cord tissue away from the injury decreased as the dose
increased. The differences in SNR were significantly different between the groups,
which received different iron doses.
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Figure 4.3: All three doses of USPIO enhanced the area of the injury, by creating
areas of signal loss (blue arrows), although there were subtle differences in enhancement
at the different doses 5mg/kg (a), 15mg/kg (b), and 30mg/kg (c) and bigger differences
in SNR (Table 4-4).
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Table 4-1: Spinal cord SNR at the different doses, from n=3 for each dose. Average
SNR is calculated from 10 images for each animal.
Dose
SNR
Fig 4.5
5mg/kg

22.7

a

15mg/kg

24.1

b

30mg/kg

17.3

c

Differences in the amount of iron accumulating at the lesion site could also been
visualized in the cord tissue at gross inspection (Figure 4.4).

Figure 4.4: In the tissue at the lesion epicenter 24hrs after USPIO injection and on day
4 after SCI there were rust-like areas that seemed to deepen in color as the dose
increased.
The FSL was measured for two SCI rats. The FSL increased between day 3 (prescan)
and day 4 (24hrs after USPIO injection) indicating that these areas had an increased
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contrast due to signal loss. Table 4.2 and Figure 4.5 show the FSL values for two SCI
rats.
Table 4-2: FSL for two animals before and after USPIO injection from an average of 5
images for each scan. FSL: average fractional signal loss, SD: standard deviation
ID

Day 3 (prescan)

Day 4 (24hrs post USPIO)

FSL

SD

FSL

SD

R5

11.1%

6.2%

42.7%

7.1%

R6

30.4%

4.6%

55.4%

5.4%

Figure 4.5: FSL in the cord in two SCI rats before and after USPIO injection from the
data presented in Table 4.1.
A color lookup table (CLUT) was used to create pseudo-colored MR images to enhance
the visualization of areas that became hypo-intense after USPIO injection (Figure 4.6). In
the prescan images (left), the cord signal intensity is more uniform. In the post USPIO
images (right) the arrows point to regions within the cord where signal loss appeared. It
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is easier to see the changes from light blue to a dark blue, as signal intensity drops in the
presence of iron, in the cord in the pseudo-colored images compared to the gray scale,
where the hue difference appears subtler.

Figure 4.6: Adjacent image slices from a representative rat spinal cord on day 3 after
SCI (prescan, left) and on day 4 after SCI (24hrs after USPIO injection at a dose of
15mg/kg, right).
Figure 4.7 shows an MRI image (a) of a SCI-only animal on day 4 after SCI with a
corresponding histological section at 5x magnification (b) stained with PPB and nuclear
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fast red. These images are centered on the lesion epicenter covering four vertebral
segments. In the MRI image, areas of signal hypo-intensity (white arrow) can be seen. In
the histological section these areas are PPB+ (black arrow). Zooming in on that region at
10x (Fig. 4.7c), 40x(Fig. 4.7d), and 100x (Fig. 4.7e) gives a closer view of that PPB+
region. The iron appears clustered in many areas and for the most part does not appear to
be intracellular.

Figure 4.7: In SCI-only animals, at day 4 after SCI, there are areas of signal loss
present in the MRI images (a), which match the PPB+ areas in histology (b). Zooming in
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on the area denoted by the square on b at 10x (c), 40x (d), and 100x (e) gives a closer
look to these regions PPB+ due to hemorrhage
In Figure 4.8, a representative bSSFP image is shown for a USPIO injected rat (a) on day
4 after SCI alongside the corresponding histological section at 5x magnification (b)
stained with PPB and nuclear fast red. In the MR image, the areas of signal hypointensity can be easily seen (white arrow) at the lesion site. In the histological section
though, at this lower magnification (5x) these areas are PPB+ (black arrow) would be
difficult to distinguish from a SCI-only animal as shown in the previous figure. This is
not surprising as there will also be hemorrhage besides the USPIO. At higher
magnification however, the appearance of the PPB staining was different from the SCI
only cord tissue. Zooming in on that region at 10x (Fig. 4.8c), 40x(Fig. 4.8d), and 100x
(Fig. 4.8e) most of the PPB+ areas look punctuate and intracellular (Fig. 4.8e, purple
arrow), an appearance not observed without USPIO injection. These are likely USPIO
particles phagocytosed by macrophages as previously shown in an ex vivo imaging study
of rat SCI.17
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Figure 4.8: In an animal that received a 30mg/kg USPIO injection the areas of signal
loss present in the MRI images (a), also match the PPB+ areas in histology (b) at day 4
after SCI. At higher magnification, on the area denoted by the square on b at 10x (c), 40x
(d), and particularly 100x (e), some of these PPB+ areas show an intracellular punctuate
pattern (purple arrows) 24hrs after USPIO injection.
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4.3 Discussion
The work performed in this chapter represents a preliminary investigation of the use of
iron oxide nanoparticles and MRI for the detection of inflammation in vivo in rat SCI. A
previous study in our lab had investigated the potential for macrophage imaging in rat
SCI by imaging ex vivo injured rat cords with bSSFP at 1.5T. Our goal here was to
implement the techniques required for in vivo imaging of macrophages in the rat at 3T
and to validate the imaging results with histology. Our strategy was to image with bSSFP
utilizing a TORO RF coil system and a high performance insertable gradient coil on a 3T
whole body scanner.
We used a USPIO agent to label cells in situ. The USPIO was administered at day 3 post
SCI and imaging was performed 24 hours later. This timeframe was selected because
histological studies have demonstrated that the number of macrophages in the injured rat
cord tissue begins to increase at 2 days post SCI and peaks between 5-7 days post SCI
with a robust macrophage presence by day 3 after SCI, which includes blood derived
macrophages.2, 17, 36-38 Furthermore, this was confirmed by a recent study that looked at
both blood and cord inflammatory cascade using flow cytometry over a period of 12hrs to
96hrs after SCI.39 In this study Stirling and Yong showed that 24hrs after SCI there was
an increase in blood monocytes that was sustained for at least 4 days after SCI. This
timing would therefore target macrophages that were infiltrating the cord. Although all
three types of commercially available iron oxide agents have now been used for
macrophage imaging we chose to use USPIO because of its relatively long circulation
time in vivo (several hours). In addition, in a pilot experiment where we tested both
USPIO and MPIO we observed more signal loss in the injured cord after USPIO and we
had some mortality after i.v. MPIO at the largest dose (30 mg/kg).
We compared three doses of USPIO: 5, 15 and 30 mg/kg body weight given i.v.
Although various USPIO has been used in rodents for many macrophage imaging studies
the use of this particular, and newly available, USPIO (Molday ION™ from BioPA L) has
not been published and so an optimal dose was not clear. Our intermediate dose was
close to the dose recommended for USPIO by Dousset et al.30 and we tested doses above
and below this. We observed an increase in the amount of signal loss within the lesion
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epicenter in the cord in images acquired after all three doses of USPIO. Although
shimming was increasingly difficult as the USPIO dose was increased, due to the high
iron content within the rat body, the highest dose of USPIO is likely the optimal since the
ability to detect macrophage infiltration will improve with greater iron content at the
lesion site.
Quantification of the signal loss due to iron remains a challenge in cellular MRI. In this
study we tested the FSL as a method to quantify the contrast of regions of signal void that
appeared in the lesion after i.v. USPIO. Essentially this measures how black the void is.
In previous studies in our lab we showed that for single iron-labeled cells there is a linear
relationship between the FSL and the iron per voxel within a particular range of
loadings.40 We found a statistically significant increase in the spinal cord lesion FSL in
cord images obtained after USPIO compared to prescans which suggests that there is an
increase in the intracellular iron content. Other models use a contralateral side for
comparison,41 but in the case of the spinal cord that was not possible, which makes it
more complicated to set thresholds or histograms. We did attempt setting a threshold
value for signal intensity so that all pixels below a certain value could be attributed to the
USPIO; however, because there was a difference in signal range from animal to animal
and between different days and doses, that was not possible; a single threshold would not
work across all cases. Measuring a volume of hypo-intense areas was also attempted by
creating a pixel histogram; though, without automatic registration and segmentation this
was not feasible to perform in all animals. Doing manual segmentation on the original
acquisition presented specific challenges in defining a range of spinal cord to cover as the
animals were not exactly aligned the same way on both days and as we got close to the
edges of the cord there were areas of signal loss due to the vertebrae that complicated the
segmentation. While it would be possible to digitally re-slice the cord into a different
plane such as axial, this presented the complication of analyzing over 500
images/animal/day. Not only was that not practical, but because the signal dropped
towards the edges of the coil some slices would need to be excluded, which presented
new challenges as the animals were not in the exact position on both days and would
need to be registered one day to the other to verify identical coverage on both days.
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In cellular MRI studies of neuroinflammation, signal loss has been attributed to the
accumulation of infiltrating iron-labeled macrophages. This is because in situ labeling is
based on the assumption that phagocytic cells in the blood during an immune response
can be targeted with an i.v. injection of (U)SPIO, and these cells will migrate to the site
of inflammation carrying the magnetic label with them. However, it is difficult to prove
that the signal loss in the cord lesion after i.v. USPIO is due to the presence of ironlabeled macrophages. We performed histology and stained the cord tissue with PPB to
detect iron. Correlating histological slices with images slices is always challenging
because not every contiguous tissue slice is sectioned and stained, and there is a large
discrepancy between the slice thicknesses (MRI=200 µm, histology =20 µm). In addition
tissues are distorted due to processing and perfect alignment is not possible. Our PPB
stained sections showed that PPB staining was observed in the cords from SCI rats that
did and did not receive USPIO, which was not surprising as in traumatic SCI a significant
amount of hemorrhage occurs. PPB staining is the classic method for demonstrating iron
in tissues and is commonly used to detect iron associated with hemorrhage. The PPB
staining looked different though in SCI cords from rats that had received i.v. USPIO
compared to those that had not. For the animals that received USPIO, most of the iron
appeared to be intracellular with little PPB staining in areas outside of cells. In rat cords
from SCI-only animals the PPB appeared in large dense clumps and appeared to have
spilled out of the parenchyma. This data suggests that after i.v. USPIO is administered in
SCI rats iron can be detected intracellularly in the cord lesion site. We cannot conclude
that we have detected macrophages however, since we have not performed a specific
stain.
To identify the cells that are being labeled with i.v. USPIO many studies have used
macrophage stains along with PPB.7, 22, 42 Several studies have compared MRI findings
with immunohistochemical analyses with ED1, a marker for activated macrophages in
rats, and showed that regions of signal loss in MR images correspond to cells in
inflammatory lesions that are ED1-positive. This may be useful for SCI as well, however,
it would not be specific since all phagocytosing macrophages (hematogenous
macrophages and microglia) in the rat are recognized by the monoclonal antibody (mAb)
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ED1. Furthermore, all of the macrophage subsets have been implicated in the
pathogenesis of SCI, are naturally phagocytic, and have the potential to internalize iron
nanoparticles.
While our intent was to label and image hematogenous macrophages, there are other cell
types that could be labeled this way. For example, microglia, the resident macrophages
in the CNS, are known to become activated in SCI and are also highly phagocytic. In
SCI the integrity of the blood-spinal cord barrier is severely compromised, and while it is
possible that nonspecific USPIO uptake could occur and is conceivable that cells already
present in the lesion at the time of USPIO administration could be labeled passively,
previous studies in MS models and patients have shown that this is unlikely.43-45 These
studies have shown no USPIO passively diffusing through a broken blood brain barrier
(BBB)43, 44 that would result in resident microglia becoming labeled and conversely have
shown USPIO enhancement in lesions with an intact BBB that could only be attributed to
infiltrating macrophages.45
Oweida et al. provided the first direct evidence that SPIO-labeled hematogenous
macrophages are labeled in situ after i.v. administration of Feridex, and that these cells
contribute to the regions of signal loss observed in MR images in a mouse model of MS.
This was achieved using a novel mouse model in which hematogenous macrophages are
GFP-positive and microglia are GFP-negative. They showed excellent correspondence
between areas in the brain that are PPB-positive and GFP-positive and regions of signal
loss observed in bSSFP brain images.46
Validation of signal loss is also challenging because there are other sources of signal
hypo-intensity in MR images. Other things appear with low signal intensity in our
bSSFP images including bone, air (e.g. lungs, trachea, occasional air pockets developed
during surgery) and artifacts (banding in bSSFP) due to inhomogeneities. In this model
in particular the lesion is an issue since there will be hemorrhage of various stages,
scarring and gliosis, all of which contribute to a heterogeneous lesion signal. The amount
of each of these pathologies will also be variable due to inherent biological differences
between animals that will have different responses to the injury. Recent strategies to
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address this challenge include the use of positive contrast agents for cell labeling47-49 and
pulse sequences that generate positive contrast from iron oxide agents.50, 51
In conclusion, in this experiment the tools required for in vivo imaging of inflammation
in SCI were implemented on a specialized imaging system at 3T. This is the first study
using cellular MRI to image cells within the lesion in vivo in a rat SCI model.
Furthermore, it was also the first demonstration of the use of bSSFP at 3T for rat body
imaging. Despite the many challenges for validating macrophage imaging with MRI our
results are promising and future work will focus on further development of these cellular
imaging techniques.
The immune response that accompanies SCI contributes to both injury and reparative
processes. The application of in vivo cellular MRI to detect cells involved in these
immune responses and to evaluate the numbers of cells and spatial patterns of cells and
changes in these markers in response to anti-inflammatory treatments would be an
extremely valuable tool for studying SCI and many other preclinical models of
inflammation and rejection.
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Chapter 5

5

Conclusion And Future Directions

5.1 Clinical Problem
Spinal cord injury (SCI) remains one of the most devastating conditions in medicine; not
only are lives lost but also there is a loss of productive life years and a high economic
burden placed on our society. It is estimated that there are 4,259 (42% traumatic and 58%
from non-traumatic causes) new SCI cases in Canada each year.1 There are many aspects
to managing SCI, including specialized medical care, comprehensive rehabilitation and
specialized equipment to increase independence and support for community reintegration.
Within the medical care aspect, there are limited therapeutic options following SCI
though recent work targeting inflammation modulation and stem cell therapy has
renewed hope that repair and recovery from central nervous system (CNS) trauma is
possible, albeit there is still a lot of work to do.2 In regards to stem cell therapy,
important, unresolved questions persist relating to the timing of the treatment, where
donor cells go after transplantation and how their contribution to the repair of neural
tissue over time can be monitored.

5.2 Significance
Magnetic resonance imaging (MRI) can be used to address these questions by producing
high-resolution images with exquisite soft tissue contrast in a non-invasive, nondestructive and three-dimensional (3D) manner, allowing a dynamic view of changing
pathology and cellular events in vivo. Furthermore, cellular MRI should allow for
optimizing of transplantation paradigms, starting with delivery efficiency and what
impact that may have for overall distribution and response to different therapies. Being
able to monitor cells in vivo in an SCI model may provide valuable information regarding
cell trafficking and changes in pathology in response to cell therapy, anti-inflammatory
treatment, or a combination of both.
One of the key aspects of this project is that it focuses on evaluating SCI and
experimental cell therapy in vivo using a clinical, whole-body MRI system. As MRI
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clinical systems have become increasingly available at hospitals, and clinical trials for
cell therapy for SCI treatment and cell tracking increase, it is important to translate the
cellular MRI technology we develop for clinical use. MRI offers the potential for noninvasive evaluation of treatment outcome at several time points making it a promising
tool for planning and optimizing anti-inflammatory treatments and to maximize stem cell
survival and engraftment during cell therapy.

5.3 Summary Of Work
This project involved in vivo imaging of SCI in mouse and rat models using a balanced
steady state free precession (bSSFP) pulse sequence and a 3T clinical scanner equipped
with a high-performance gradient coil insert. The imaging technology was optimized to
allow longitudinal studies in SCI models of both mice and rats. This approach was used
to assess direct multipotent mesenchymal stromal cell (MSC) transplantation in a mouse
model and acute inflammation in a rat model. The specific aspects of each chapter are
summarized below.

5.3.1

In Vivo MRI Of SCI In The Mouse (Chapter 2)

In Chapter 2 the feasibility of performing high-resolution in vivo MRI to visualize the
injured mouse spinal cord using a bSSFP pulse sequence, in a clip compression injury
model, was presented. High-resolution mouse cord images were used to detect and
monitor the cord lesions for 6 weeks after SCI. The epicenter of the injury appeared as a
region of mixed signal intensities on day 2 post-SCI. Regions of signal hypo-intensity
appeared at the lesion site by 2 weeks post-SCI and became more apparent with time. In
some mice, large cyst-like lesions were detected rostral to the lesion epicenter, as early as
2 weeks post-SCI, and increased in volume with time. In addition, MRI was used to
detect and monitor iron-labeled MSC after their transplantation into the injured cord.
MSC appeared as large, obvious regions of signal loss in the cord, which decreased in
size over time. This was the first study to use cellular MRI for cell tracking in vivo in a
mouse SCI model.
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5.3.2

The Use Of Cellular MRI To Track The Fate Of Iron-Labeled
MSC After Direct Transplantation In A Mouse Model Of SCI
(Chapter 3)

In Chapter 3, the fate of iron-labeled MSC was tracked with MRI after their direct
transplantation into mice with SCI. SCI mice received a direct transplant of (1) live MSC
labeled with micron-sized iron oxide particles (MPIO); (2) dead, MPIO-labeled MSC; (3)
unlabeled MSC; or (4) free MPIO and were imaged at 3T for 6 weeks after
transplantation. Live, iron-labeled MSC appeared as a well-defined region of signal loss
in the mouse spinal cord at the site of transplant. However, the MR appearance of dead,
iron-labeled MSC and free iron particles was similar and persisted for the 6 weeks of the
study. While iron-labeled stem cells could be detected and monitored in vivo after direct
transplantation into the injured spinal cord of mice, the fate of the iron label was not
clear. Our investigation indicated that caution should be taken when interpreting MR
images after direct transplantation of iron-labeled cells in SCI. Areas of signal loss were
not detected in other organs outside the CNS but in a few animals that received live
MPIO-labeled MSC signal loss was observed along the dorsal edge of the cord in the
cervical spinal cord, possibly within the CSF.

5.3.3

In Vivo MRI Of Acute Inflammation After SCI In The Rat: A
Preliminary Study (Chapter 4)

In Chapter 4 a preliminary investigation was performed to evaluate techniques for
macrophage imaging using cellular MRI in a traumatic SCI model in the rat. A clip
compression SCI was induced in 16 female Wistar rats and they were scanned using a 3D
bSSFP pulse sequence with 200x200x200µm resolution 3 days after SCI. Molday IONTM,
an ultra-small super superparamagnetic iron oxide (USPIO) blood pool agent, was
injected at 3 different doses: 5mg/kg (n=3), 15mg/kg (n=7), and 30mg/kg (n=3); 5 control
rats were not injected. 24 hours later the rats were imaged again. Areas of signal
heterogeneity at the epicenter were identified in images of all animals on day 3 and at day
4 in images of controls. In the animals that received USPIO, additional areas appeared
hypo-intense on day 4 where the signal loss was more pronounced. Fractional signal loss
(FSL) was a robust measurement to compare differences in signal hypo-intensity before
and after the USPIO injection. Histology showed intracellular iron in these animals,
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which suggested that the increased signal loss observed after the injection was due to
intracellular iron accumulation at the lesion site, possibly from macrophages that
phagocytized the iron agent. Being able to follow this cell infiltration over time may
contribute to understand changes in timing, severity and patterns as a response to
potential treatments.
While most studies in rat SCI models are done at higher field scanners,3-6 we showed the
feasibility of doing this using a clinical scanner at a high resolution. The fact that the
present study was done in vivo in a reasonable period of time, with multiple scans and
without animal mortality lays a foundation to explore potential treatments such as cell
therapy and anti-inflammatory drug intervention.

5.4 Future directions
The work presented in this thesis opens up different paths for further investigation
regarding cellular MRI in SCI research.
One of the questions regarding cell therapy for SCI treatment is optimal delivery method.
Different routes have been used such as intra-arterial,7 intravenous,8 lumbar puncture,9
and direct transplantation.10 However, there is no clear picture of which, if any, would
produce optimal results. We have shown here how cellular MRI can be used to better
understand the fate of administered stem cells. From the moment of transplantation we
were able to verify cell delivery to the target, which as de Vries et al. have reported, may
be of crucial importance for therapy success.11 Thus, the techniques here developed could
be applied to compare different transplantation sites and techniques. We were also able to
observe distribution to other tissues, which might help get a better understanding of the
homing of the cells and whether that is required for the trophic and immunomodulatory
effects that stem cells can provide. Especially after the report of increased pain and
spasticity by Kishk et al.,12 upon cell transplantation, being able to monitor cells over
time at a high resolution could give us a clearer picture of their distribution. Things to
investigate might include if cells are going to the sensory tracts, for example, and if this is
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an undesirable target to home to. As one of the differences among the early clinical
studies has been dose difference that would be certainly another thing to compare in the
future with longitudinal studies as shown here.
One of the limitations in this study was establishing the long-term fate of the cells, as we
could not distinguish viable and non-viable cells or iron transfer several weeks after the
transplant. Recent studies have investigated the ability to differentiate between live and
dead cells based on changes in relaxation times, and contrast, when iron goes from being
compartmentalized to free in solution.13,

14

These techniques may be useful for

monitoring cell death in transplantation studies, however, they have yet to be validated in
vivo. An alternative exciting new development that could be incorporated in cell tracking
in SCI models is the use of MRI reporter genes. A recent study used embryonic stem
cells transduced with a reporter gene that can be targeted with an iron oxide conjugated
antibody to provide information on cell viability, by providing differences in contrast
from viable cells, even as they divided and differentiated, compared to apoptotic cells.15
Another study used ferritin as a reporter gene by transducing stem cells to overexpress
ferritin and then transplanted them into a myocardial infarction model where the authors
reported the possibility of tracking stem cells as they divide and differentiate while being
able to track morpho-functional changes in the heart.16 Additional information on cell
viability specific to the transplanted cells while maintaining MRI sensitivity would
certainly be useful for cell transplantation in SCI models such as the ones here presented.
This would help track changes in the cord and lesion while simultaneously track cell
viability.
Better understanding macrophage response is important for planning anti-inflammatory
treatments and cell therapy.17 Imaging macrophage infiltration in vivo will contribute to
better understand their role in SCI and consider it when optimizing treatments. In the case
of SCI where there can be different sources of hyper- and hypo- intensity due to
pathological features of the injury, like edema and hemorrhage combined MRI protocols
may also help distinguish between iron labeled cells and other sources of hypo-intensity.
Susceptibility weighted imaging,18,

19

for instance, has shown the ability to detect

hemorrhage in SCI20 and would be worth trying to distinguish between areas of signal
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loss from different sources. The development of new pulse sequences, which generate
positive contrast from iron-labeled cells, could also be incorporated to the techniques
here developed to better define the signal from iron-labeled cells.21, 22
The FSL measurement provided useful information for monitoring increased iron in the
SCI lesion; it was significantly greater in the cord images after USPIO administration.
However, FSL does not provide rigorous quantification of iron present. New algorithms
are being developed for iron quantification,23 such as phase gradient mapping to estimate
iron concentration. Implementing algorithms for cord registration and segmentation
would certainly improve the ability to quantify the changes observed in signal due to
USPIO. We have previously used lesion volume measurements in a rat model ex vivo to
assess an anti-inflammatory treatment.24 A significant difference in the lesion volume
was measured for treated versus untreated SCI rats. We have now shown that it is
possible to image the rat in vivo and label cells in situ. Combining this technology of in
vivo imaging with long-term follow-up of SCI pathological features could be used to
compare treatments; for example, how stem cell therapy might impact cavity formation in
the chronic phase.
SCI is certainly a complex condition and in the end, it is most likely that a combination of
treatments and a comprehensive rehabilitation will maximize the chances of functional
recovery and thus improve quality of life of individuals who deal daily with the obstacles
it poses. There are still questions to be addressed in a wide variety of treatments25, 26 and
in a field where clinical translation and longitudinal monitoring is so important to decide
which of these treatments to take forward to clinical trials, cellular MRI could certainly
be an important part of this process. As these tools are refined, they can be used to test
different treatments (MSC, mobilization agents, anti-inflammatory or combinations) and
use information obtained from MRI to establish best treatment time-points to optimize
treatment effects.
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